Nuvve Holding (NVVE) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 04, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-40296
Entity Registrant Name	NUVVE HOLDING CORP.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-1617000
Entity Address, Address Line One	2468 Historic Decatur Road,
Entity Address, City or Town	San Diego,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92106
City Area Code	(619)
Local Phone Number	456-5161
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,167,124
Amendment Flag	false
Entity Central Index Key	0001836875
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NVVE
Security Exchange Name	NASDAQ
Warrants
Document Information [Line Items]
Title of 12(b) Security	Warrants to Purchase Common Stock
Trading Symbol	NVVEW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 11,846,458	$ 15,753,896
Restricted cash	480,000	480,000
Accounts receivable, net	2,550,890	1,121,694
Inventories	10,032,242	11,551,831
Prepaid expenses	1,328,189	1,487,582
Other current assets	1,959,286	1,454,563
Total Current Assets	28,197,065	31,849,566
Property and equipment, net	607,504	636,944
Intangible assets, net	1,306,781	1,341,640
Investment in equity securities	670,951	1,670,951
Investment in leases	95,250	97,054
Right-of-use operating lease assets	5,192,320	5,305,881
Financing receivables	288,872	288,872
Security deposit, long-term	8,682	8,682
Total Assets	36,367,425	41,199,590
Current Liabilities
Accounts payable	2,363,548	2,390,422
Accrued expenses	4,329,062	3,347,399
Deferred revenue	1,183,092	1,221,497
Operating lease liabilities - current	850,821	824,326
Other liabilities	108,096	113,844
Total Current Liabilities	8,834,619	7,897,488
Operating lease liabilities - noncurrent	4,979,748	5,090,170
Warrants liability	434,642	220,884
Derivative liability - non-controlling redeemable preferred shares	436,065	359,225
Other long-term liabilities	469,190	393,179
Total Liabilities	15,154,264	13,960,946
Commitments and Contingencies
Mezzanine equity
Redeemable non-controlling interests, preferred shares, zero par value, 1,000,000 shares authorized, 3,138 shares issued and outstanding at March 31, 2023 and December 31, 2022; aggregate liquidation preference of $3,533,898 and $3,464,606 at March 31, 2023 and December 31, 2022, respectively	3,709,231	3,547,765
Stockholders’ Equity
Common stock, $0.0001 par value, 100,000,000 shares authorized; 24,984,404 and 24,272,150 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	2,498	2,427
Additional paid-in capital	146,094,334	144,073,505
Accumulated other comprehensive income	85,116	76,182
Accumulated deficit	(124,622,921)	(116,956,528)
Nuvve Holding Corp. Stockholders’ Equity	21,559,027	27,195,586
Non-controlling interests	(4,174,656)	(3,950,186)
Total Stockholders’ Equity	17,384,371	23,245,400
Total Liabilities, Mezzanine Equity and Stockholders’ Equity	36,367,425	41,199,590
Class D Incentive Units
Mezzanine equity
Class D Incentive units, zero par value, 1,000,000 units authorized; 50,000 and 250,000 units issued and outstanding at March 31, 2023 and December 31, 2022, respectively	119,559	445,479
Cumulative Preferred Stock
Stockholders’ Equity
Preferred stock, $0.0001 par value, 1,000,000 shares authorized; zero shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Temporary equity, par value (in Dollars per share)	$ 0	$ 0
Temporary equity, shares authorized (in Shares)	1,000,000	1,000,000
Temporary equity, shares issued (in Shares)	3,138	3,138
Temporary equity, shares outstanding (in Shares)	3,138	3,138
Temporary equity, liquidation preference	$ 3,533,898	$ 3,464,606
Preferred stock par value (in Dollars per share)	$ 0.0001
Preferred stock, shares authorized (in Shares)	1,000,000
Common stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in Shares)	100,000,000	100,000,000
Common stock, shares issued (in Shares)	24,984,404	24,272,150
Common stock, shares outstanding (in Shares)	24,984,404	24,272,150
Class D Incentive Units
Temporary equity, par value (in Dollars per share)	$ 0	$ 0
Temporary equity, shares authorized (in Shares)	1,000,000	1,000,000
Temporary equity, shares issued (in Shares)	50,000	250,000
Temporary equity, shares outstanding (in Shares)	50,000	250,000
Cumulative Preferred Stock
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in Shares)	1,000,000	1,000,000
Preferred stock, shares issued (in Shares)	0	0
Preferred stock, shares outstanding (in Shares)	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue
Total revenue	$ 1,854,786	$ 2,371,033
Operating expenses
Cost of product and service revenue	1,460,904	2,142,312
Selling, general, and administrative	6,172,024	7,625,550
Research and development	2,100,088	2,135,575
Total operating expenses	9,733,016	11,903,437
Operating loss	(7,878,230)	(9,532,404)
Other income (expense)
Interest income	68,337	1,458
Change in fair value of warrants liability	(213,758)	4,776,000
Change in fair value of derivative liability	(76,840)	53,472
Other, net	440,386	(29,787)
Total other income, net	218,125	4,801,143
Loss before taxes	(7,660,105)	(4,731,261)
Income tax expense	0	0
Net loss	(7,660,105)	(4,731,261)
Less: Net income (loss) attributable to non-controlling interests	6,288	(100,933)
Net loss attributable to Nuvve Holding Corp.	(7,666,393)	(4,630,328)
Less: Preferred dividends on redeemable non-controlling interests	69,292	64,015
Less: Accretion on redeemable non-controlling interests preferred shares	161,466	161,466
Net loss attributable to Nuvve Holding Corp. common stockholders	$ (7,897,151)	$ (4,855,809)
Net loss per share attributable to Nuvve Holding Corp. common stockholders, basic (in Dollars per share)	$ (0.32)	$ (0.26)
Net loss per share attributable to Nuvve Holding Corp. common stockholders, diluted (in Dollars per share)	$ (0.32)	$ (0.26)
Weighted-average shares used in computing net loss per share attributable to Nuvve Holding Corp. common stockholders, basic (in Shares)	24,596,181	18,864,374
Weighted-average shares used in computing net loss per share attributable to Nuvve Holding Corp. common stockholders, diluted (in Shares)	24,596,181	18,864,374
Products and services
Revenue
Total revenue	$ 1,780,385	$ 2,253,784
Grants
Revenue
Total revenue	$ 74,401	$ 117,249

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (7,660,105)	$ (4,731,261)
Other comprehensive (loss) income, net of taxes
Foreign currency translation adjustments, net of taxes	8,934	(13,684)
Total Comprehensive loss	(7,651,171)	(4,744,945)
Less: Comprehensive income (loss) attributable to non-controlling interests	6,288	(100,933)
Comprehensive loss attributable to Nuvve Holding Corp.	(7,657,459)	(4,644,012)
Less: Preferred dividends on redeemable non-controlling interests	(69,292)	(64,015)
Less: Accretion on redeemable non-controlling interests preferred shares	(161,466)	(161,466)
Comprehensive loss attributable to Nuvve Holding Corp. common stockholders	$ (7,426,701)	$ (4,418,531)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Non-controlling Interests
Balances (in Shares) at Dec. 31, 2021		18,861,130
Balances at Dec. 31, 2021	$ 27,012,445	$ 1,888	$ 122,336,607	$ 113,446	$ (92,937,863)	$ (2,501,633)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options and vesting of restricted stock (in shares)		30,370
Exercise of stock options and vesting of restricted stock	3	$ 3
Stock-based compensation	1,455,641		1,455,641
Currency translation adjustment	(13,684)			(13,684)
Preferred dividends - non-controlling interest	(64,015)					(64,015)
Accretion on redeemable non-controlling interests preferred shares	(161,466)					(161,466)
Net loss	(4,731,261)				(4,630,328)	(100,933)
Balances (in Shares) at Mar. 31, 2022		18,891,500
Balance at Mar. 31, 2022	23,497,663	$ 1,891	123,792,248	99,762	(97,568,191)	(2,828,047)
Balances (in Shares) at Dec. 31, 2021		18,861,130
Balances at Dec. 31, 2021	27,012,445	$ 1,888	122,336,607	113,446	(92,937,863)	(2,501,633)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	36,900,000
Balances (in Shares) at Dec. 31, 2022		24,272,150
Balance at Dec. 31, 2022	23,245,400	$ 2,427	144,073,505	76,182	(116,956,528)	(3,950,186)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options and vesting of restricted stock (in shares)		91,300
Exercise of stock options and vesting of restricted stock	0	$ 9	(9)
Stock-based compensation	1,414,183		1,414,183
Currency translation adjustment	8,934			8,934
Preferred dividends - non-controlling interest	(69,292)					(69,292)
Accretion on redeemable non-controlling interests preferred shares	(161,466)					(161,466)
Proceeds from Direct Offering, net of offering costs (in shares)		543,478
Proceeds from Direct Offering, net of offering costs	470,000	$ 54	469,946
Proceeds from Direct Offering, net of offering costs		78,638
Proceeds from common stock offering, net of offering costs	136,717	$ 8	136,709
Net loss	(7,660,105)				(7,666,393)	6,288
Balances (in Shares) at Mar. 31, 2023		24,985,566
Balance at Mar. 31, 2023	$ 17,384,371	$ 2,498	$ 146,094,334	$ 85,116	$ (124,622,921)	$ (4,174,656)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net loss	$ (7,660,105)	$ (4,731,261)	$ 36,900,000	$ 27,200,000
Adjustments to reconcile to net loss to net cash used in operating activities
Depreciation and amortization	76,520	67,302
Stock-based compensation	965,820	1,455,644
Change in fair value of warrants liability	213,758	(4,776,000)
Change in fair value of derivative liability	76,840	(53,472)
Gains from sale of investments in equity securities	(325,155)	0
Noncash lease expense	115,576	178,849
Change in operating assets and liabilities
Accounts receivable	(1,427,503)	454,849
Inventory	1,519,589	1,789,982
Prepaid expenses and other assets	(342,511)	(915,356)
Accounts payable	(28,178)	(2,521,672)
Accrued expenses	1,021,709	624,722
Deferred revenue	(38,062)	(23,476)
Net cash used in operating activities	(5,831,702)	(8,449,889)	(34,100,000)	(29,200,000)
Investing activities
Purchase of property and equipment	(11,125)	(250,861)
Proceeds from sale of investments in equity securities	1,325,155	0
Net cash provided (used) in investing activities	1,314,030	(250,861)
Financing activities
Proceeds from Direct Offering of common stock, net of offering costs	470,000	0
Proceeds from common stock offering, net of offering costs	136,717	0
Payment of finance lease obligations	(1,896)	(2,073)
Net cash provided (used) in financing activities	604,821	(2,073)
Effect of exchange rate on cash	5,413	146,949
Net decrease in cash and restricted cash	(3,907,438)	(8,555,874)
Cash and restricted cash at beginning of year	16,233,896	32,740,520	32,740,520
Cash and restricted cash at end of period	12,326,458	24,184,646	$ 16,233,896	$ 32,740,520
Supplemental Disclosure of Noncash Financing Activity
Transfer of inventory to property and equipment	$ 0	$ 87,095

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Description of Business Nuvve Holding Corp., a Delaware corporation headquartered in San Diego, California (the “Company” or “Nuvve”), was founded on November 10, 2020 under the laws of the state of Delaware. On March 19, 2021, the Company (at the time known as NB Merger Corp.) acquired the outstanding shares of Nuvve Corporation (“Nuvve Corp.”), and the Company changed its name to Nuvve Holding Corp. Structure of the Company Nuvve has two wholly owned subsidiaries, Nuvve Corp. and Nuvve Pennsylvania LLC. Nuvve Corp. has four wholly owned subsidiaries: (1) Nuvve Denmark ApS, (“Nuvve Denmark”), a company registered in Denmark, (2) Nuvve SaS, a company registered in France, (3) Nuvve KK (Nuvve Japan), a company registered in Japan, and (4) Nuvve LTD, a company registered in United Kingdom. Nuvve Norway, a company registered in Norway is a branch of Nuvve Denmark. On August 4, 2021, the Company formed Levo Mobility LLC, a Delaware limited liability company ("Levo"), with Stonepeak Rocket Holdings LP, a Delaware limited partnership ("Stonepeak"), and Evolve Transition Infrastructure LP, a Delaware limited partnership ("Evolve"). Levo is a consolidated entity of the Company. Please see Note 2 for the principles of consolidation. Levo is a sustainable infrastructure company focused on rapidly advancing the electrification of transportation by funding vehicle-to-grid ("V2G") enabled Electric Vehicle ("EV") fleet deployments. Levo utilizes Nuvve’s V2G technology and conditional capital contribution commitments from Stonepeak and Evolve to offer Fleet-as-a-Service ("FaaS") for school buses, last-mile delivery, ride hailing and ride sharing, municipal services, and more to eliminate the primary barriers to EV fleet adoption including large upfront capital investments and lack of expertise in securing and managing EVs and associated charging infrastructure. Levo's turnkey solution simplifies and streamlines electrification, can lower the total cost of EV operation for fleet owners, and supports the grid when the EVs are not in use. For a fixed monthly payment with no upfront cost, Levo will provide the EVs, such as electric school buses, charging infrastructure powered by Nuvve’s V2G platform, EV and charging station maintenance, energy management, and technical advice. Levo initially focuses on electrifying school buses, providing associated charging infrastructure, and delivering V2G services to enable safer and healthier transportation for children while supporting carbon dioxide emission reduction, renewable energy integration, and improved grid resiliency.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies For a detailed discussion about the Company’s significant accounting policies, see Note 2, “ Summary of Significant Accounting Policies ,” in the Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”). During the three months ended March 31, 2023, there were no significant updates made to the Company’s significant accounting policies. Basis of Presentation The accompanying (i) unaudited condensed consolidated balance sheet as of December 31, 2022, which has been derived from audited financial statements, and (ii) unaudited interim condensed financial statements have been prepared in accordance pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Therefore, it is suggested that these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes in the 2022 Form 10-K, filed with the SEC on March 31, 2023. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, comprehensive loss, cash flows, and stockholders’ equity for the interim periods, but are not necessarily indicative of the results to be anticipated for the full year 2023 or any future period. In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the unaudited condensed consolidated financial statements are issued. Since inception, the Company has incurred recurring losses and negative cash flows from operations and has an accumulated deficit of $124.6 million as of March 31, 2023. Nuvve incurred operating losses of approximately $7.9 million as of the three months ended March 31, 2023, and $36.9 million and $27.2 million for the years ended December 31, 2022, and 2021, respectively. Nuvve cash used in operations were $5.8 million as of the three months ended March 31, 2023, and $34.1 million and $29.2 million for the years ended December 31, 2022, and 2021, respectively. As of March 31, 2023, Nuvve had a cash balance, working capital, and stockholders’ equity of $11.8 million, $19.4 million and $17.4 million, respectively. The Company continues to expect to generate operating losses and negative cash flows and may need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful expanded commercialization of the Company's Grid Integrated Vehicle ("GIVe") platform and the achievement of a level of revenues adequate to support its cost structure. Management plans to fund current operations through increased revenues and if required cash saving measures and or raising additional capital. Management's expectations with respect to the Company’s ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. There is an inherent risk that the Company may not achieve such financial projections and if so, cash outflows could be higher than currently anticipated. Should this occur, management plans to implement cash saving measures during this time period, including reductions in discretionary expenses related to consultants, travel, personnel, and personnel-related costs. If necessary, management believes it can raise additional capital through its at-the-market offering agreement. However, as such plans are not solely within management’s control management cannot conclude as of the date of this filing that the plans are probable of being successfully implemented and as such has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for twelve months from the date of issuance of our financial statements. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Principles of Consolidation The condensed consolidated financial statements include the accounts and operations of the Company, its wholly owned subsidiaries and its consolidated variable interest entity. All intercompany accounts and transactions have been eliminated upon consolidation. Variable Interest Entities Pursuant to the consolidation guidance, the Company first evaluates whether it holds a variable interest in an entity in which it has a financial relationship and, if so, whether or not that entity is a variable interest entity ("VIE"). A VIE is an entity with insufficient equity at risk for the entity to finance its activities without additional subordinated financial support or in which equity investors lack the characteristics of a controlling financial interest. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company concludes that it is the primary beneficiary and consolidates the VIE if the Company has both (i) the power to direct the activities of the VIE that most significantly influence the VIE's economic performance, and (ii) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. The Company formed Levo with Stonepeak and Evolve, in which the Company owns 51% of Levo's common units. The Company has determined that Levo is a VIE in which the Company is the primary beneficiary. Accordingly, the Company consolidates Levo and records a non-controlling interest for the share of the entity owned by Stonepeak and Evolve. Assets and Liabilities of Consolidated VIEs The Company's condensed consolidated financial statements include the assets, liabilities and results of operations of VIEs for which the Company is the primary beneficiary. The other equity holders’ interests are reflected in "Net income (loss) attributable to non-controlling interests" in the condensed consolidated statements of operations and "Non-controlling interests" in the condensed consolidated balance sheets. See Note 18 for details of non-controlling interests. The Company began consolidating the assets, liabilities and results of operations of Levo during the quarter ended September 30, 2021. The creditors of the consolidated VIE do not have recourse to the Company other than to the assets of the consolidated VIEs. The following table summarizes the carrying amounts of Levo assets and liabilities included in the Company’s condensed consolidated balance sheets at March 31, 2023: March 31, 2023 December 31, 2022 Assets Cash $ 27,505 $ 27,629 Prepaid expenses and other current assets 28,608 59,794 Total Assets $ 56,113 $ 87,423 Liabilities Accounts payable $ 6,000 $ 8,165 Accrued expenses and dividend payable 401,198 336,713 Derivative liability - non-controlling redeemable preferred shares 436,065 359,225 Total Liabilities $ 843,263 $ 704,103 Redeemable Non-Controlling Interest - Mezzanine Equity Redeemable non-controlling interest represents the shares of the preferred stock issued by Levo to Stonepeak and Evolve (the "preferred shareholders"), who own 49% of Levo common units. The preferred stock is not mandatorily redeemable or currently redeemable, but it could be redeemable with the passage of time at the election of Levo, the preferred shareholders or a triggering event as defined in the preferred stock agreement. As a result of the contingent put right available to the preferred shareholders, the redeemable non-controlling interests in Levo are classified as mezzanine equity in the Company’s unaudited condensed consolidated balance sheets. The initial carrying value of the redeemable non-controlling interest is reported at the initial proceeds received on issuance date, reduced by the fair value of embedded derivatives resulting in an adjusted initial carrying value. The adjusted initial carrying value is further adjusted for the accretion of the difference with the redemption price value using the effective interest method. The accretion amount is a deemed dividend recorded against retained earnings or, in its absence, to additional-paid-in-capital. The carrying amount of the redeemable non-controlling interest is measured at the higher of the carrying amount adjusted each reporting period for income (or loss) attributable to the non-controlling interest, or the carrying amount adjusted each reporting period by the accretion amount. See Note 18 for details. Non-controlling interests The Company presents non-controlling interests as a component of equity on its condensed consolidated balance sheets and reports the portion of its earnings or loss for non-controlling interest as net earnings or loss attributable to non-controlling interests in the condensed consolidated statements of operations. Emerging Growth Company Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) permits emerging growth companies (“EGC”) to delay complying with new or revised financial accounting standards that do not yet apply to private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act). The Company qualifies as an EGC. The JOBS Act provides that an EGC can elect to opt-out of the extended transition period and comply with the requirements that apply to non-EGCs, but any such election to opt-out is irrevocable. The Company has elected not to opt-out of such an extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an EGC, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This different adoption timing may make a comparison of the Company’s financial statements with another public company, which is neither an EGC nor an EGC that has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include the impairment of intangible assets, the net realizable value of inventory, the fair value of share-based payments, lease incremental borrowing rate, derivative liability associated with redeemable preferred shares, revenue recognition, the fair value of warrants, and the recognition and disclosure of contingent liabilities. Management evaluates its estimates on an ongoing basis. Actual results could materially vary from those estimates. Cash and Restricted Cash The Company maintains cash balances that can, at times, exceed amounts insured by the Federal Deposit Insurance Corporation, which is up to $250,000. The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area. In connection with a new office lease agreement, the Company was required to provide an irrevocable, unconditional letter of credit to the landlord upon execution of the lease. The amount securing the letter of credit was recorded as restricted cash as of March 31, 2023 and December 31, 2022 was $480,000 . Concentrations of Credit Risk At March 31, 2023 and December 31, 2022, the financial instruments which potentially expose the Company to concentration of credit risk consist of cash in financial institutions (in excess of federally insured limits) and trade receivables. The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable, as follows: For the three months ended March 31, 2023 one customer accounted for 58.9% of revenue. For the three months ended March 31, 2022 one customer in accounted for 72.8% o f revenue. During the three months ended March 31, 2023, the Company's top five customers accounted for approximately 76.5% o f the Company’s total revenue. During the three months ended March 31, 2022, the Company's top five customers accounted for approximately 87.5% o f the Company’s total revenue. At March 31, 2023 , one customer accounted f or 45.6% of accounts receivable. At December 31, 2022, three customers in aggregate accounted for 40.6% of a ccounts receivable. Approximat ely 69.2% and 53.6% of the Company’s trade accounts receivable balance was with five customers at March 31, 2023 and December 31, 2022 , respectively. The Company estimates its maximum credit risk for accounts receivable at the amount recorded on the balance sheet. The trade accounts receivables are generally short-term and all probable bad debt losses have been appropriately considered in establishing the allowance for doubtful accounts. Recently adopted accounting pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires, among other things, the use of a new current expected credit loss ("CECL") model in determining the allowances for doubtful accounts with respect to accounts receivable, accrued straight-line rent receivable, and notes receivable. The CECL model requires that an entity estimate its lifetime expected credit loss with respect to these receivables and record allowances that, when deducted from the balance of the receivables, represent the net amounts expected to be collected. Entities will also be required to disclose information about how the entity developed the allowances, including changes in the factors that influenced its estimate of expected credit losses and the reasons for those changes. The Company adopted the guidance effective beginning January 1, 2023. The adoption of the guidance did not have a material impact on its condensed consolidated financial statements. Recently issued accounting pronouncements not yet adopted None applicable

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The disclosures below discuss the Company’s material revenue contracts. The following table provides information regarding disaggregated revenue: Three Months Ended March 31, 2023 2022 Revenue recognized over time: Services $ 351,499 $ 194,650 Grants 74,401 117,249 Revenue recognized at point in time: Products 1,428,886 2,059,134 Total revenue $ 1,854,786 $ 2,371,033 The aggregate am ount of revenue for the Company’s existing contracts and grants with customers as of March 31, 2023 expected to be recognized in the future, and classified as deferred revenue on the condensed consolidated balance sheet, for year ended December 31, is as follows (this disclosure does not include revenue related to contracts whose original expected duration is one year or less): 2023 (remaining nine months) $ 177,132 Thereafter 1,005,960 Total $ 1,183,092 The Company operates in a single business segment, which is the EV V2G Charging segment. The following table summarizes the Company’s revenues by geography: Three Months Ended March 31, 2023 2022 Revenues: United States $ 1,758,453 $ 2,227,734 United Kingdom 32,982 37,390 Denmark 63,351 105,909 $ 1,854,786 $ 2,371,033 The following table summarizes the Company’s intangible assets and property, plant and equipment in different geographic locations: March 31, December 31, Long-lived assets: United States $ 1,735,901 $ 1,795,267 United Kingdom 3,866 1,335 Denmark 174,518 181,982 $ 1,914,285 $ 1,978,584

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following are the liabilities measured at fair value on the condensed consolidated balance sheet at March 31, 2023 and December 31, 2022 using quoted price in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3): Level 1: Level 2: Level 3: Total at March 31, Total Gains (Losses) For The Three Months Ended March 31, 2023 Recurring fair value measurements Private warrants $ — $ — $ 1,000 $ 1,000 $ 1,000 Stonepeak and Evolve unvested warrants $ — $ — $ — $ — $ — Institutional/Accredited Investor warrants $ — $ — $ 433,642 $ 433,642 $ (214,758) Derivative liability - non-controlling redeemable preferred shares $ — $ — $ 436,065 $ 436,065 $ (76,840) Total recurring fair value measurements $ — $ — $ 870,707 $ 870,707 $ (290,598) Level 1: Level 2: Level 3: Total at December 31, Total Gains (Losses) For The Three Months Ended March 31, 2022 Recurring fair value measurements Private warrants $ — $ — $ 2,000 $ 2,000 $ 433,000 Stonepeak and Evolve unvested warrants $ — $ — $ — $ — 4,343,000 Institutional/Accredited Investor warrants $ — $ — $ 218,884 $ 218,884 $ — Derivative liability - non-controlling redeemable preferred shares $ — $ — $ 359,225 $ 359,225 $ 53,472 Total recurring fair value measurements $ — $ — $ 580,109 $ 580,109 $ 4,829,472 The following is a reconciliation of the opening and closing balances for the liabilities related to the warrants (Note 11 ) and derivative liability - non-controlling redeemable preferred shares measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2023: Private warrants Stonepeak and Evolve unvested warrants Institutional/Accredited Investor warrants Non-controlling redeemable preferred shares - derivative liability Balance at December 31, 2022 $ 2,000 $ — $ 218,884 $ 359,225 Total (gains) losses for period included in earnings (1,000) — 214,758 76,840 Balance at March 31, 2023 $ 1,000 $ — 433,642 $ 436,065 The fair value of the level 3 Private Warrants was estimated at March 31, 2023 using the Black-Scholes model which used the following inputs: term of 2.97 years, risk free rate of 3.82%, no dividends, volatility of 62.0%, and strike price of $11.50. The fair value of the level 3 Private Warrants was estimated at December 31, 2022 using the Black-Scholes model which used the following inputs: term of 3.22 years, risk free rate of 4.20%, no dividends, volatility of 67.0%, and strike price of $11.50. The fair value of the level 3 Institutional/Accredited Investor warrants was estimated at March 31, 2023 using the Black-Scholes model which used the following inputs: term of 4.80 years, risk free rate of 3.62%, no dividends, volatility of 64.0%, common stock price of $0.70, and strike price of $3.75. The fair value of the level 3 Institutional/Accredited Investor Warrants was estimated at December 31, 2022 using the Black-Scholes model which used the following inputs: term of 5.10 years, risk free rate of 3.97%, no dividends, volatility of 62.0%, common stock price of $0.50, and strike price of $3.75. The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve unvested warrants at March 31, 2023: Series C Unvested Warrants Series D Unvested Warrants Series E Unvested Warrants Series F Unvested Warrants Fair value (in millions) $— $— $— $— Valuation methodology Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Capital expenditure forecast (in millions) $— $— $— $— Probability of warrants vesting (a) —% —% —% —% __________________ (a) During the second quarter ended June 30, 2022, the Company significantly lowered its forecast of Levo's capital deployments due to the passage by the United States Congress of the Infrastructure Investment and Jobs Act bill, and the related unveiling of the Environmental Protection Agency’s 2022 Clean School Bus rebates. The resulting lower forecast of capital deployments reduced the probabilities of the future vesting of the unvested warrants. Therefore, at March 31, 2023, the Company has determined that it is unlikely that the unvested warrants will vest. The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve unvested warrants at March 31, 2022: Series C Unvested Warrants Series D Unvested Warrants Series E Unvested Warrants Series F Unvested Warrants Fair value (in millions) $1.7 $1.2 $0.8 $0.6 Valuation methodology Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Term (years) 9.10 9.10 9.10 9.10 Risk free rate 2.3% 2.3% 2.3% 2.3% Exercise price $15.0 $20.0 $30.0 $40.0 Volatility 56.0% 56.0% 56.0% 56.0% Capital expenditure forecast (in millions) $125.0 $250.0 $375.0 $500.0 Probability of warrants vesting 90.8% 76.0% 63.8% 54.4% The fair value of the level 3 derivative liability - non-controlling redeemable preferred shares are estimated at March 31, 2023 using the M onte Carlo Simulation model which used the following inputs: terms range from 1.34 years to 7.0 years, risk free rate of 3.6%, no dividends, volatility of 65.0% and probability of redemptions triggered of 75.0%. The fair value of the level 3 derivative liability - non-controlling redeemable preferred shares are estimated at March 31, 2022 using the M onte Carlo Simulation model which used the following inputs: terms range from 3.00 years to 7.0 years, risk free rate of 2.4%, no dividends, volatility of 56.0% and probability of redemptions triggered of 75.0%. There were no transfers between Level 1 and Level 2 of the fair value hierarchy in 2023 and 2022. Cash, accounts receivable, accounts payable, and accrued expenses are generally carried on the cost basis, which management believes approximates fair value due to the short-term maturity of these instruments.

Derivative Liability - Non-Cont

Derivative Liability - Non-Controlling Redeemable Preferred Stock	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability - Non-Controlling Redeemable Preferred Stock	Derivative Liability - Non-Controlling Redeemable Preferred Stock The Company has determined that the redemption features embedded in the non-controlling redeemable preferred stock is required to be accounted for separately from the redeemable preferred stock as a derivative liability. Separation of the redemption features as a derivative liability is required because its economic characteristics and risks are considered more akin to a debt instrument, and therefore, not considered to be clearly and closely related to the economic characteristics of the redeemable preferred stock. The economic characteristics of the redemption features are considered more akin to a debt instrument because the minimum redemption value could be greater than the face amount, the redemption features are contingently exercisable, and the shares carry a fixed mandatory dividend. Accordingly, the Company has recorded an embedded derivative liability representing the estimated fair value of the right of the holders to exercise their redemption option upon the occurrence of a redemption event. The embedded derivative liability is adjusted to reflect fair value at each period end with changes in fair value recorded in the “Change in fair value of derivative liability” financial statement line item of the company’s condensed consolidated statements of operations. For additional information on the non-controlling redeemable preferred stock, see Note 18 . The following table displays the fair value of derivatives by balance sheet line item: March 31, 2023 December 31, 2022 Derivative liability - non-controlling redeemable preferred shares $ 436,065 $ 359,225

Investments

Investments	3 Months Ended
	Mar. 31, 2023
Investments [Abstract]
Investments	Investments The Company accounts for its 13% equity ownership in Dreev as an investment in equity securities without a readily determinable fair value subject to impairment. The Company has a consulting services agreement with Dreev related to software development and operations. The consulting services were zero fo r each of the three months ended March 31, 2023 and 2022. The consulting services are being provided to Dreev at the Company’s cost and is recognized, as other income, net in the condensed consolidated statements of operations. In accordance with an advanced subscription agreement dated June 6, 2022, the Company invested $1.0 million in Switch EV Ltd ("Switch"), a nonpublic entity incorporated and registered in the United Kingdom through an advance subscription agreement for a future equity ownership expected be more or less than 5% subject to final valuations. Switch will automatically award the Company the equity ownership with conversion shares in equity upon its completion of either a financing round, company sale or IPO, or dissolution event. The Company is expected to account for the investment as an investment in equity securities without a readily determinable fair value subject to impairment. The Company and Switch intend to collaborate in the future to integrate technologies for the advancement of V2G. On March 30, 2023, the Company sold its investment interest in Switch for $1.3 million. A gain of $0.3 million was recorded in Other, net on the statements of operations.

Account Receivables, Net

Account Receivables, Net	3 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
Account Receivables, Net	Account Receivables, Net The following tables summarizes the Company's accounts receivable: March 31, 2023 December 31, 2022 Trade receivables $ 2,609,724 $ 1,180,528 Less: allowance for credit losses (58,834) (58,834) Accounts receivable, net $ 2,550,890 $ 1,121,694 Allowance for doubtful accounts: Balance December 31, 2022 $ (58,834) Provision — Write-off — Recoveries — Balance March 31, 2023 $ (58,834)

Inventories

Inventories	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories The following table summarizes the Company’s inventories balance by category: March 31, 2023 December 31, 2022 DC Chargers $ 7,710,610 $ 9,248,398 AC Chargers 200,170 123,247 Vehicles - School Buses 1,620,000 1,620,000 Others 501,462 560,186 Total $ 10,032,242 $ 11,551,831

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment The following table summarizes the Company’s property, plant and equipment balance: Useful Lives March 31, 2023 December 31, 2022 Computers & Servers 1 year to 3 years $ 136,026 $ 130,417 Vehicles 5 years to 7 years 139,788 139,788 Office furniture and equipment 3 years to 5 years 332,161 326,613 Others (1) 5 years to 7 years 259,280 256,685 Total 867,255 853,503 Less: Accumulated Depreciation (259,751) (216,559) Property, plant and equipment, net $ 607,504 $ 636,944 March 31, 2023 March 31, 2022 Depreciation expense $ 49,958 $ 25,975 __________________

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets At both March 31, 2023 and December 31, 2022, the Company had recorded a gross intangible asset balance of $2,091,556, which is related to patent and intangible property rights acquired. Amortization expense of intangible assets was $34,859 for the three months ended March 31, 2023 and 2022, respectively. Accumulated amortization totaled $784,775 and $749,916 at March 31, 2023 and December 31, 2022, respectively. The net amount of intangible assets of $1,306,781 at March 31, 2023, will be amortized over the weighted average remaining life of 9.6 years . Total estimated future amortization expense is as follows: 2023 (remaining nine months) $ 104,577 2024 139,437 2025 139,437 2026 137,770 2027 132,770 Thereafter 652,790 $ 1,306,781

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	Stockholders’ Equity As of March 31, 2023, the Company has authorized two classes of stock, Common Stock, and Preferred Stock. The total number of shares of all classes of capital stock which the Company has authority to issue is 101,000,000, of which 100,000,000 authorized shares are Common Stock with a par value of $0.0001 per share (“Common Stock”), and 1,000,000 authorized shares are Preferred Stock of the par value of $0.0001 per share (“Preferred Stock”). Please see Note 11, “ Stockholders' Equity ,” in the Notes to Consolidated Financial Statements included in the Company’s 2022 Form 10-K for a detailed discussion of the Company’s stockholders' equity. Shelf Registration On April 25, 2022, the Company filed a shelf registration statement with the SEC which will allow it to issue unspecified amounts of common stock, preferred stock, warrants for the purchase of shares of common stock or preferred stock, debt securities, and units consisting of any combination of any of the foregoing securities, in one or more series, from time to time and in one or more offerings up to a total dollar amount of $100.0 million. The shelf registration statement was declared effective on May 5, 2022. The Company believes that it will be able to raise capital by issuing securities pursuant to its effective shelf registration statement. January 2023 ATM Offering Program On January 31, 2023, the Company entered into an At the Market Offering Agreement (the “ATM Agreement”) with Craig-Hallum Capital Group LLC (“Craig-Hallum”), as the sales agent (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares of its common stock (the “Shares”), having an aggregate offering price of up to $25,000,000. The Company paid the Agent a commission of 3.0% of the aggregate gross sales prices of the Shares. The Company reimbursed the Agent for fees and disbursements of its legal counsel in the amount of $50,000. During the three months ended March 31, 2023, the Company sold 78,638 shares of common stock pursuant to the ATM Agreement at an average price of $1.79 per share for aggregate net proceeds of approximately $0.1 million. February 2023 Registered Direct Offering On February 17, 2023, the Company entered into a subscription agreement (the “Subscription Agreement”) with a certain institutional and accredited investor, relating to the issuance and sale of 543,478 shares of common stock in a registered direct offering (the “February 2023 Offering”). The offering price for the shares was $0.92 per share of common stock. The closing of the February 2023 Offering occurred on February 21, 2023. The aggregate gross proceeds from the February 2023 Offering was approximately $0.5 million. Chardan Capital Markets LLC acted as the placement agent for the February 2023 Offering and received a sales commission of 6.0% of the gross proceeds. Securities Purchase Agreement, Pre-Funded Warrants and Warrants On July 27, 2022, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional and accredited investor (the “Purchaser”), relating to the issuance and sale of 2,150,000 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), pre-funded warrants to purchase an aggregate of 1,850,000 shares of Common Stock (the “Pre-Funded Warrants”), and warrants (the “Warrants”) to purchase an aggregate of 4,000,000 shares of Common Stock in a registered direct offering (the “Offering”). The offering closed on July 29, 2022. The aggregate gross proceeds to the Company from the offering were approximately $14.0 million and net proceeds were approximately $13.1 million , excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants and the Warrants. The Pre-Funded Warrants were exercised as of December 31, 2022. The Warrants have an exercise price of $3.75 per share of common stock, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions, and each Warrant is exercisable for one share of Common Stock. The Warrants are exercisable beginning six months from the date of issuance and terminates five years from the initial exercisability date. The Warrants are recorded as a liability in the consolidated balance sheet at fair value, with changes in fair value recorded in the condensed consolidated statement of operations. See Note 4 for details of changes in fair value of the unvested warrants recorded in the condensed consolidated statement of operations. Warrants - Stonepeak and Evolve On May 17, 2021, in connection with the signing of a letter of agreement, relating to the formation of Levo (the "Letter Agreement"), the Company issued to Stonepeak and Evolve ten year warrants to purchase common stock (allocated 90% to Stonepeak and 10% to Evolve). See below for details. The grant-date fair value of the warrants issued to Stonepeak and Evolve were: series B $12.8 million, series C $5.6 million, series D $4.8 million, series E $3.8 million and series F $3.2 million. The fair values of the vested warrants are recorded in the condensed consolidated balance sheets in additional-paid-in capital in stockholders' equity as the vested warrants are indexed to the Company’s common stock and meet the conditions for equity classification. The unvested warrants are recorded as a liability in the condensed consolidated balance sheets at fair value, with changes in fair value recorded in the condensed consolidated statements of operations as the unvested warrants are deemed not to be indexed to the Company’s common stock. See Note 4 for details of changes in fair value of the unvested warrants recorded in the condensed consolidated statement of operations. The Company issued to Stonepeak and Evolve the following ten year warrants to purchase common stock (allocated 90% to Stonepeak and 10% to Evolve): • Series B warrants to purchase 2,000,000 shares of the Company’s common stock, at an exercise price of $10.00 per share, which are fully vested upon issuance, • Series C warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $15.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $125 million in aggregate capital expenditures, • Series D warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $20.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $250 million in aggregate capital expenditures, • Series E warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $30.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $375 million in aggregate capital expenditures, and • Series F warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $40.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $500 million in aggregate capital expenditures. The warrants may be exercised at any time on or after the date that is 180 days after the applicable vesting date. Securities Purchase Agreement On May 17, 2021, in connection with the signing of the Letter Agreement, the Company entered into a Securities Purchase Agreement with Stonepeak and Evolve which provide them from time to time between November 13, 2021 and November 17, 2028, in their sole discretion, to purchase up to an aggregate of $250 million in shares of the Company’s common stock at a purchase price of $50.00 per share (allocated 90% to Stonepeak and 10% to Evolve). See below f or details. The grant-date fair value of the Securities Purchase Agreement to purchase shares of the Company’s common stock was $12.6 million, and is recorded in the condensed consolidated balance sheet as equity in additional-paid-in capital as it is indexed to the Company’s common stock and meets the conditions for equity classification . In connection with the signing of the Letter Agreement, as reference above, the Company also entered into a Securities Purchase Agreement (the “SPA”) and a Registration Rights Agreement (the “RRA”) with Stonepeak and Evolve. • The SPA includes customary representations and warranties and closing conditions and customary indemnification provisions. In addition, Stonepeak and Evolve may elect to purchase shares under the SPA on a cashless basis in the event of a change of control of the Company. Warrants - Public and Private In connection with its initial public offering on February 19, 2020, Newborn sold 5,750,000 units, which included one warrant to purchase Newborn’s common stock (the “Public Warrants”). Also, on February 19, 2020, NeoGenesis Holding Co., Ltd., Newborn’s sponsor (“the Sponsor”), purchased an aggregate of 272,500 private units, each of which included one warrant (the “Private Warrants”), which have the same terms as the Public Warrants. Upon completion of the merger between Nuvve and Newborn, the Public Warrants and Private Warrants were automatically converted to warrants to purchase Common Stock of the Company. The terms of the Private Warrants are identical to the Public Warrants as described above, except that the Private Warrants are not redeemable so long as they are held by the Sponsor or its permitted transferees. Concurrently with the execution of the Merger Agreement on November 11, 2020, Newborn entered into subscription agreements with certain accredited investors pursuant to which the investors agreed to purchase 1,425,000 of Newborn’s common stock, at a purchase price of $10.00 per share, for an aggregate purchase price of $14,250,000 (the "PIPE"). Upon closing of the PIPE immediately prior to the closing of the Business Combination, the PIPE investors also received 1.9 PIPE Warrants to purchase the Company’s Common Stock for each share of Common Stock purchased. The PIPE Warrants are each exercisable for one-half of a common share at $11.50 per share and have the same terms as described above for the Public Warrants. The PIPE investors received demand and piggyback registration rights in connection with the securities issued to them. Because the Private Warrants have dissimilar terms with respect to the Company’s redemption rights depending on the holder of the Private Warrants, the Company determined that the Private Warrants are required to be carried as a liability in the condensed consolidated balance sheet at fair value, with changes in fair value recorded in the condensed consolidated statement of operations. The Private Warrants are reflected as a liability in the condensed consolidated balance sheet as of March 31, 2023 and the change in the fair value of the Private Warrants is reflect ed in the condensed consolidated statement of operations. See Note 4 for details of changes in fair value of the Private Warrants recorded in the condensed consolidated statement of operations. The following table is a summary of the number of shares of the Company’s Common Stock issuable upon exercise of warrants outstanding at March 31, 2023: Number of Number of Number of Exercise Expiration Public Warrants 2,875,000 — 2,875,000 $11.50 March 19, 2026 Private Warrants 136,250 — 136,250 $11.50 March 19, 2026 PIPE Warrants 1,353,750 — 1,353,750 $11.50 March 19, 2026 Stonepeak/Evolve Warrants - series B 2,000,000 — 2,000,000 $10.00 May 17, 2031 Stonepeak/Evolve Warrants - series C 1,000,000 — 500,000 $15.00 May 17, 2031 Stonepeak/Evolve Warrants - series D 1,000,000 — 500,000 $20.00 May 17, 2031 Stonepeak/Evolve Warrants - series E 1,000,000 — 500,000 $30.00 May 17, 2031 Stonepeak/Evolve Warrants - series F 1,000,000 — 500,000 $40.00 May 17, 2031 Institutional/Accredited Investor Warrants 4,000,000 — 4,000,000 $3.75 July 29, 2027 14,365,000 12,365,000 Unit Purchase Option On February 19, 2020, Newborn sold to the underwriters of its initial public offering for $100, a unit purchase option ("UPO") to purchase up to a total of 316,250 units at $11.50 per unit (or an aggregate exercise price of $3,636,875) commencing on the date of Newborn's initial business combination, March 19, 2021, and expiring February 13, 2025. Each unit issuable upon exercise of the UPO consists of one and one-tenth of a share of the Company's common stock and one warrant to purchase one share of the Company's common stock at the exercise price of $11.50 per share. The warrant has the same terms as the Public Warrant. In no event will the Company be required to net cash settle the exercise of the UPO or the warrants underlying the UPO. The holders of the unit purchase option have demand and "piggy back" registration rights for periods of five ASC 815-40, Derivatives and Hedging-Contracts in an Entity’s Own Equity, as the UPO is indexed to the Company’s common stock and meets the conditions for equity classification.

Stock Option Plan

Stock Option Plan	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock Option Plan	Stock Option Plan In 2010, the Company adopted the 2010 Equity Incentive Plan (the “2010 Plan”), which provides for the grant of restricted stock awards, stock options, and other share-based awards to employees, consultants, and directors. In November 2020, the Company’s Board of Directors extended the term of the 2010 Plan to July 1, 2021. In 2021, the Company adopted the 2020 Equity Incentive Plan (the “2020 Plan”), which provides for the grant of restricted stock awards, incentive and non-statutory stock options, and other share-based awards to employees, consultants, and directors. As of March 31, 2023, there is an aggregate of 3,300,000 common shares reserved for issuance under the 2020 Plan. All options granted to date have a ten year contractual life and vesting terms of four years. In general, vested options expire if not exercised 90 days after termination of service. As of March 31, 2023, a total of 677,176 shares of common stock remained available for future issuance under the 2020 Plan. Forfeitures are accounted for as it occurs. Stock-based compensation expense recognized in selling, general, and administrative, and research and development are as follows: Three Months Ended March 31, 2023 2022 Options $ 682,948 $ 822,106 Restricted stock 596,161 613,839 Total $ 1,279,109 $ 1,435,945 The following is a summary of the stock option activity under the 2010 Plan for the three months ended March 31, 2023: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2022 853,507 2.91 5.70 — Granted — — — — Exercised — — — — Forfeited (1,328) 2.11 — — Expired/Cancelled (14,601) 8.71 — — Outstanding - March 31, 2023 837,578 2.83 5.46 — Options Exercisable at March 31, 2023 796,154 2.54 4.22 — Option Vested at March 31, 2023 796,154 2.54 4.22 — The weighted-average grant-date fair value of options granted during the three months ended March 31, 2023 was zero. The following is a summary of the stock option activity under the 2020 Plan for the three months ended March 31, 2023: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2022 1,711,112 11.71 8.46 — Granted — — — — Exercised — — — — Forfeited (10,575) 4.23 — — Expired/Cancelled (5,062) 11.96 — — Outstanding - March 31, 2023 1,695,475 11.75 8.22 — Options Exercisable at March 31, 2023 706,125 13.25 7.98 — Option Vested at March 31, 2023 706,125 13.25 7.98 — The weighted-average grant-date fair value of options granted during the three months ended March 31, 2023 was zero. During the year ended December 31, 2021, 1,640,000 options were modified to lower the exercise price by $0.60 per share, which resulted in $246,000 of incremental compensation cost to be recognized over the remaining vesting period. The amount of additional compensation expense for the three months ended March 31, 2023, was $12,632. The amount of additional compensation expense for the three months ended March 31, 2022, was $19,699. Other Information: Three Months Ended 2023 2022 Amount received from option exercised $ — $ — March 31, 2023 Weighted average remaining recognition period Total unrecognized options compensation costs $ 5,484,305 2.34 No amounts relating to the Plan have been capitalized. Compensation cost is recognized over the requisite service period based on the fair value of the options. A summary of the status of the Company’s nonvested restricted stock units as of December 31, 2022, and changes during the three months ended March 31, 2023, is presented below: Shares Weighted- Nonvested at December 31, 2022 436,259 6.43 Granted 102,319 0.96 Vested/Release (139,259) 4.19 Cancelled/Forfeited — — Nonvested and Outstanding at March 31, 2023 399,319 5.81 As of March 31, 2023, there was $1,365,948 of total unrecognized compensation cost related to nonvested restricted stock. The Company expects to recognize this compensation cost over a remaining weighted-average period of approximately 0.77 years.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Three Months Ended March 31, 2023 2022 Income tax expense $ — $ — Effective tax rate 0.0 % 0.0 % The effective tax rate used for interim periods is the estimated annual effective tax rate, based on current estimate of full year results, except that taxes related to specific events, if any, are recorded in the interim period in which they occur. The effective tax rate differed from the U.S. federal statutory tax rate primarily due to operating losses that receive no tax benefit as a result of a valuation allowance recorded for such losses. The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes (“ASC 740”). Under the provisions of ASC 740, management is required to evaluate whether a valuation allowance should be established against its deferred tax assets. The Company currently has a full valuation allowance against its deferred tax assets. As of each reporting date, the Company’s management considers new evidence, both positive and negative, that could impact management’s view with regard to future realization of deferred tax assets. For the three months ended March 31, 2023, there was no material change from the year ended December 31, 2022 in the amount of the Company’s deferred tax assets that are not considered to be more likely than not to be realized in future years.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders The following table sets forth the calculation of basic and diluted net loss per share attributable to common stockholders during the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 2022 Net loss attributable to Nuvve Holding Corp. common stockholders $ (7,897,151) $ (4,855,809) Weighted-average shares used to compute net loss per share attributable to Nuvve common stockholders, basic and diluted 24,596,181 18,864,374 Net Loss per share attributable to Nuvve common stockholders, basic and diluted $ (0.32) $ (0.26) The following outstanding shares of common stock equivalents were excluded from the calculation of the diluted net loss per share attributable to Nuvve common stockholders because their effect would have been anti-dilutive: Three Months Ended March 31, 2023 2022 Stock options issued and outstanding 2,533,053 2,773,734 Nonvested restricted stock issued and outstanding 399,319 880,892 Public warrants 2,875,000 2,875,000 Private warrants 136,250 136,250 PIPE warrants 1,353,750 1,353,750 Stonepeak and Evolve warrants 6,000,000 6,000,000 Stonepeak and Evolve options 5,000,000 5,000,000 Institutional/Accredited Investor Warrants 4,000,000 — Total 22,297,372 19,019,626

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Parties	Related Parties As described in Note 6 , the Company holds equity interests in and provides certain consulting services to Dreev, an entity in which a stockholder of the Company owns the other portion of Dreev’s equity interests. During the three months ended March 31, 2023 and 2022, the Company recognized re venue of $65,670 and $28,000, respectively, from an entity that is an investor in the Company. The Company had a balance of accounts receivable of approximately zero at both March 31, 2023 and December 31, 2022 from the same entity that is an investor in the Company.

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	Leases The Company has entered into leases for commercial office spaces and vehicles. These leases are not unilaterally cancellable by the Company, are legally enforceable, and specify fixed or minimum amounts. The leases expire at various dates through 2031 and provide for renewal options. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. The leases provide for increases in future minimum annual rental payments based on defined increases in the Consumer Price Index, subject to certain minimum increases. Also, the agreements generally require the Company to pay real estate taxes, insurance, and repairs. Supplemental unaudited condensed consolidated balance sheet information related to leases is as follows: Classification March 31, 2023 December 31, 2022 Operating lease assets Right-of-use operating lease assets $ 5,192,320 5,305,881 Finance lease assets Property, plant and equipment, net 17,284 18,467 Total lease assets $ 5,209,604 $ 5,324,348 Operating lease liabilities - current Operating lease liabilities - current $ 850,821 824,326 Operating lease liabilities - noncurrent Operating lease liabilities - noncurrent 4,979,748 5,090,170 Finance lease liabilities - current Other liabilities 7,284 7,184 Finance lease liabilities - noncurrent Other long-term liabilities 11,818 12,959 Total lease liabilities $ 5,849,671 $ 5,934,639 The components of lease expense are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2023 2022 Operating lease expense Selling, general and administrative $ 228,633 $ 176,520 Finance lease expense: Amortization of finance lease assets Selling, general and administrative 1,423 5,940 Interest on finance lease liabilities Interest expense 493 639 Total lease expense $ 230,549 $ 183,099 Operating Lease Finance Lease Maturities of lease liabilities are as follows: March 31, 2023 March 31, 2023 2023 $ 661,418 $ 5,463 2024 892,212 7,284 2025 893,046 7,284 2026 921,273 1,821 2027 946,683 — Thereafter 3,798,554 — Total lease payments 8,113,186 21,852 Less: interest (2,282,617) (2,750) Total lease obligations $ 5,830,569 $ 19,102 Lease term and discount rate: March 31, 2023 December 31, 2022 Weighted-average remaining lease terms (in years): Operating lease 8.5 9.0 Finance lease 3.0 3.3 Weighted-average discount rate: Operating lease 7.8% 7.8% Finance lease 7.8% 7.8% Other Information: Three Months Ended March 31, Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows - operating leases $ 113,561 $ 62,269 Operating cash flows - finance leases $ 2,015 $ 639 Financing cash flows - finance leases $ 1,896 $ 2,073 Leased assets obtained in exchange for new finance lease liabilities $ 17,284 $ 23,550 Leased assets obtained in exchange for new operating lease liabilities $ — $ — Sublease In April 2022, the Company entered into a sublease agreement with certain local San Diego companies to sublease a portion of the Company's 4,811 square foot expansion. The term of the sublease is six months to twelve months with fixed base rental income ranging from $2,250 to $14,500 per month. The sublease has no option for renewal or extension at the end of the sublease term. Sublease income are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2023 2022 Sublease lease income Other, net $ 129,770 $ — Lessor In February 2022, the Company entered into a 10 year master services agreement ("MSA") with a certain school district for FaaS to electrify their school bus fleet. A statement of work (“SOW”) for engineering, procurement and construction ("EPC") was also executed in conjunction with the MSA. As part of this SOW, the Company will provide electric vehicle supply equipment ("EVSE") and related warranties, infrastructure engineering and construction, installation of EVSE, and subscription services to Nuvve’s V2G GIVe platform. The MSA has both lease and non-lease components. The lease component is the EVSE and non-lease components are the EPCs. The Company accounted for the lease components as a sale-type lease with the investment in lease of $95,250 and zero at March 31, 2023 and 2022, respectively . Lease income are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2023 2022 Lease income Products and services $ 1,070 $ — Interest income Products and services 2,595 — Total lease income $ 3,665 $ —
Leases	Leases The Company has entered into leases for commercial office spaces and vehicles. These leases are not unilaterally cancellable by the Company, are legally enforceable, and specify fixed or minimum amounts. The leases expire at various dates through 2031 and provide for renewal options. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. The leases provide for increases in future minimum annual rental payments based on defined increases in the Consumer Price Index, subject to certain minimum increases. Also, the agreements generally require the Company to pay real estate taxes, insurance, and repairs. Supplemental unaudited condensed consolidated balance sheet information related to leases is as follows: Classification March 31, 2023 December 31, 2022 Operating lease assets Right-of-use operating lease assets $ 5,192,320 5,305,881 Finance lease assets Property, plant and equipment, net 17,284 18,467 Total lease assets $ 5,209,604 $ 5,324,348 Operating lease liabilities - current Operating lease liabilities - current $ 850,821 824,326 Operating lease liabilities - noncurrent Operating lease liabilities - noncurrent 4,979,748 5,090,170 Finance lease liabilities - current Other liabilities 7,284 7,184 Finance lease liabilities - noncurrent Other long-term liabilities 11,818 12,959 Total lease liabilities $ 5,849,671 $ 5,934,639 The components of lease expense are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2023 2022 Operating lease expense Selling, general and administrative $ 228,633 $ 176,520 Finance lease expense: Amortization of finance lease assets Selling, general and administrative 1,423 5,940 Interest on finance lease liabilities Interest expense 493 639 Total lease expense $ 230,549 $ 183,099 Operating Lease Finance Lease Maturities of lease liabilities are as follows: March 31, 2023 March 31, 2023 2023 $ 661,418 $ 5,463 2024 892,212 7,284 2025 893,046 7,284 2026 921,273 1,821 2027 946,683 — Thereafter 3,798,554 — Total lease payments 8,113,186 21,852 Less: interest (2,282,617) (2,750) Total lease obligations $ 5,830,569 $ 19,102 Lease term and discount rate: March 31, 2023 December 31, 2022 Weighted-average remaining lease terms (in years): Operating lease 8.5 9.0 Finance lease 3.0 3.3 Weighted-average discount rate: Operating lease 7.8% 7.8% Finance lease 7.8% 7.8% Other Information: Three Months Ended March 31, Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows - operating leases $ 113,561 $ 62,269 Operating cash flows - finance leases $ 2,015 $ 639 Financing cash flows - finance leases $ 1,896 $ 2,073 Leased assets obtained in exchange for new finance lease liabilities $ 17,284 $ 23,550 Leased assets obtained in exchange for new operating lease liabilities $ — $ — Sublease In April 2022, the Company entered into a sublease agreement with certain local San Diego companies to sublease a portion of the Company's 4,811 square foot expansion. The term of the sublease is six months to twelve months with fixed base rental income ranging from $2,250 to $14,500 per month. The sublease has no option for renewal or extension at the end of the sublease term. Sublease income are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2023 2022 Sublease lease income Other, net $ 129,770 $ — Lessor In February 2022, the Company entered into a 10 year master services agreement ("MSA") with a certain school district for FaaS to electrify their school bus fleet. A statement of work (“SOW”) for engineering, procurement and construction ("EPC") was also executed in conjunction with the MSA. As part of this SOW, the Company will provide electric vehicle supply equipment ("EVSE") and related warranties, infrastructure engineering and construction, installation of EVSE, and subscription services to Nuvve’s V2G GIVe platform. The MSA has both lease and non-lease components. The lease component is the EVSE and non-lease components are the EPCs. The Company accounted for the lease components as a sale-type lease with the investment in lease of $95,250 and zero at March 31, 2023 and 2022, respectively . Lease income are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2023 2022 Lease income Products and services $ 1,070 $ — Interest income Products and services 2,595 — Total lease income $ 3,665 $ —

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Legal Matters The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including product liability claims. Management believes that any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the financial condition or results of operations of the Company. Please see Note 17(e) below for details regarding a legal proceeding currently pending with a Company supplier. (b) Research Agreement Effective September 1, 2016, the Company is party to a research agreement with a third party, which is also a Company stockholder, whereby the third party will perform research activity as specified annually by the Company. Under the terms of the agreement, the Company paid a minimum of $400,000 annually in equal quarterly installments. For the three months ended March 31, 2023 and 2022, $133,333 and $100,000, respectively, w ere paid under the research agreement. In October 2022, the agreement was renewed for one year through August 2023. At March 31, 2023, $166,667 remained to be paid under the renewed agreement. (c) In-Licensing The Company is a party to a licensing agreement for non-exclusive rights to intellectual property which will expire at the later of the date at which the last patent underlying the intellectual property expires or 20 years from the sale of the first licensed product. Under the terms of the agreement, the Company will pay up to an aggregate of $700,000 in royalties upon achievement of certain milestones. As of March 31, 2023 and December 31, 2022, no royalty expenses had been incurred under this agreement . In November 2017, the Company executed an agreement ("IP Acquisition Agreement") with the University of Delaware ("Seller") whereby all rights, title, and interest in the licensed intellectual property was assigned to the Company in exchange for an upfront fee of $500,000 and common shares valued at $1,491,556. The total acquisition cost of $1,991,556 was capitalized and is being amortized over the fifteen year expected life of the patents underlying the intellectual property. Under the terms of the agreement, the Company will pay up to an aggregate $7,500,000 in royalties to the Seller upon achievement of milestones, related to the aggregate number of vehicles that have had access to the Company’s GIVe platform system for a period of at least six consecutive months, and for which the Company has received monetary consideration for such access pursuant to a subscription or other similar agreement with the vehicle’s owner as follows: Milestone Event: Aggregated Vehicles Milestone 10,000 $ 500,000 20,000 750,000 40,000 750,000 60,000 750,000 80,000 750,000 100,000 1,000,000 200,000 1,000,000 250,000 2,000,000 $ 7,500,000 The Seller will retain a non-exclusive, royalty-free license, to utilize the intellectual property solely for research and education purposes. As of March 31, 2023, no royalty expenses had been incurred under this agreement. (d) Investment The Company is committed to possible future additional contributions to the Investment in Dreev ( Note 6 ) in the amount of $270,000. (e) Purchase Commitments On July 20, 2021, Nuvve issued a purchase order (“PO”) to its supplier, Rhombus Energy Solutions, Inc. (“Rhombus”), for a quantity of DC fast chargers and dispensers for EVs (the “DC Chargers”), for a total price of $13.2 million, with the delivery date specified as the week of November 15, 2021. However, the supplier subsequently notified Nuvve that it would be unable to meet the contracted delivery date as a result of supply chain issues. The parties therefore agreed to change the delivery date to on or about December 15, 2021. As of the end of December 31, 2021, Nuvve received a partial shipment of the DC Chargers, for which Nuvve paid $6.3 million. The delivered DC Chargers did not fully conform to required software and hardware specifications. In April 2022, the parties agreed to address the technical issues necessary to bring the DC charges into full conformity with specifications, and to amend the mix defined in the original PO for the delivery of the remaining DC Chargers still subject to the original PO. As of March 31, 2023 , the supplier is still in the process of bringing the delivered DC Chargers into full conformance. No amendments to the original PO have been executed. To the extent Nuvve and the supplier are unable to align on mutually agreeable terms to resolve the dispute relating to the PO, Nuvve believes it has no obligation to purchase or accept delivery against the PO given that the supplier failed to timely deliver conforming DC Chargers in accordance with the stated PO terms. The supplier asserts, however, that the original PO was non-cancellable and non-refundable regardless of the DC Chargers’ delivery date, and regardless of any non-conformance. On November 2, 2022, Rhombus filed a demand for arbitration against the Company for breach of contract in connection with the dispute. Rhombus has alleged the Company failed to pay certain purchase orders for D.C. electric vehicle chargers (“V2G Chargers”) totaling $5.0 million. In response, the Company has asserted counterclaims for breach of express warranty, fraudulent inducement (misrepresentation), fraudulent inducement (concealment), violation of California’s Business and Professions Code § 17200, promissory estoppel, and unjust enrichment. The Company has alleged Rhombus fraudulently induced the Company into the purchase of the V2G Chargers by both omitting certain facts including but not limited to Rhombus’ inability to develop, commission, maintain, and service the technology necessary to provide V2G Chargers conforming to those promised under the parties’ contract. Rhombus and the Company are actively engaged in discovery. A final arbitration hearing date has not yet been set, but we expect it to be scheduled for the fourth quarter of 2023. Nuvve believes the supplier’s position does not have merit and Nuvve intends to exercise all available rights and remedies in its defense. The outcome of any such proceeding is inherently uncertain, and the amount and/or timing of any liability or expense resulting from such a proceeding is not reasonably estimable at this time. In addition, regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors.

Non-Controlling Interest

Non-Controlling Interest	3 Months Ended
	Mar. 31, 2023
Noncontrolling Interest [Abstract]
Non-Controlling Interest	Non-Controlling Interest For entities that are consolidated, but not 100% owned, a portion of the net income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the net income or loss and corresponding equity that is not owned by the Company is included in non-controlling interests in the condensed consolidated financial statements. Non-controlling interests are presented outside as a separate component of stockholders’ equity on the Company’s condensed consolidated balance sheets. The primary components of non-controlling interests are separately presented in the Company’s condensed consolidated statements of changes in stockholders’ equity to clearly distinguish the interest in the Company and other ownership interests in the consolidated entities. Net income or loss includes the net income or loss attributable to the holders of non-controlling interests on the Company’s condensed consolidated statements of operations. Net income or loss is allocated to non-controlling interests in proportion to their relative ownership interests. Levo Series B Redeemable Preferred Stock Levo is authorized to issue 1,000,000 shares of series B preferred stock at no par value. The Series B Preferred Stock (a) pays a dividend, when, as and if declared by Levo's Board of Directors, of 8.0% per annum of the stated value per share, payable quarterly in arrears, (b) has an initial stated value of $1,000 per share, and dividends are paid in cash. Levo accrues for undeclared and unpaid dividends as they are payable in accordance with the terms of the Certificate of Designations filed with the Secretary of State of the State of Delaware. At March 31, 2023, Levo had accumulated unpaid accrued preferred dividends of $395,898, included in accrued liabilities, on 3,138 issued and outstanding shares of Series B Preferred Stock. Series B Preferred Stock is not a participating or convertible securities. Series B Preferred Stock is not currently redeemable but it could be redeemable with the passage of time at the election of Levo or the preferred shareholders or upon the occurrence of a trigger event as defined in the preferred stock agreement. Since the redeemable preferred stock may be redeemed by the preferred shareholders or upon the occurrence of a trigger event that is not solely within the control of Levo, but is not mandatorily redeemable; therefore, based on its characteristics, Levo has classified the Series B Preferred Stock as mezzanine equity. At March 31, 2023, Series B Preferred Stock consisted of the following: Shares Authorized Shares Issued and Outstanding Stated Value per Share Initial Carrying Value Cumulative Unpaid Accrued Preferred Dividends Liquidation Preference 1,000,000 3,138 $ 1,000 $ 3,138,000 $ 395,898 $ 3,533,898 The Company has determined that the redemption features embedded in the non-controlling redeemable preferred stock is required to be accounted for separately from the redeemable preferred stock as a derivative liability. See Note 5 for detail disclosure of the derivative liability. The redeemable preferred stock has been initially recognized at fair value of $3,138,000, the proceeds on the date of issuance. This amount has been further reduced by $497,606, the fair value of the embedded derivative liability at date of issuance, resulting in an adjusted initial value of $2,640,394. Levo is accreting the difference between the adjusted carrying initial value and the redemption price value over the seven-year period from date of issuance of August 4, 2021 through July 4, 2028 (the date at which the preferred shareholders have the unconditional right to redeem the shares, deemed to be the earliest likely redemption date) using the effective interest method. The accretion to the carrying value of the redeemable preferred stock is treated as a deemed dividend, recorded as a charge to retained earnings of Levo. During the three months ended March 31, 2023, Levo accreted $161,466 resulting in the carrying value of the redeemable preferred stock of $3,709,231. The following table summarizes Levo non-controlling interests presented as a separate component of stockholders’ equity on the Company’s condensed consolidated balance sheet at March 31, 2023: March 31, 2023 December 31, 2022 Balance at December 31, 2022 $ (3,950,186) (2,501,633) Net income (loss) attributable to non-controlling interests $ 6,288 (538,841) Less: dividends paid to non-controlling interests 69,292 263,846 Less: Preferred share accretion adjustment 161,466 645,866 Non-controlling interests $ (4,174,656) $ (3,950,186) The following table summarizes Levo non-controlling interests presented as a separate component of the Company’s condensed consolidated statements of operations as of March 31, 2023: Three Months Ended March 31, 2023 2022 Net income (loss) attributable to non-controlling interests $ 6,288 $ (100,933) Redeemable Non-controlling Interest Reconciliation — Mezzanine Equity March 31, 2023 December 31, 2022 Beginning balance $ 3,547,765 $ 2,901,899 Preferred share Accretion adjustment 161,466 645,866 Ending balance $ 3,709,231 $ 3,547,765 Profits Interests Units (Class D Incentive Units) In April 2022, Levo issued Class D Incentive Units to certain key employees in the form of profits interests within the meaning of the Internal Revenue Service (“Profits Interests”). Any future distributions under the Profits Interests will only occur once distributions made to all other member units exceed a threshold amount. The Company performed an analysis of the key features of the Profits Interests to determine whether the nature of the Profits Interests are (a) an equity award which should be accounted for under ASC 718, Compensation – Stock Compensation or (b) a bonus arrangement which should be accounted for under ASC 710, Compensation – General . Based on the features of the Profits Interests, the awards are considered stock compensation to be accounted for as equity. Accordingly, compensation expense for the Profits Interests will be recognized over the vesting period of the awards. Subject to the grantee not incurring a termination prior to the applicable vesting date, the Incentive Units will vest as follows: (i) 80% of the Incentive Units will vest in equal 25.0% installments on each of the first four (4) anniversaries of the grant date (such that 80% of the total number of Incentive Units issued to the grantee hereunder will be vested on the fourth anniversary of the Grant Date) and (ii) the remaining 20% of the Incentive Units will vest upon a Change of Control. Therefore, the expenses recorded will only reflect the 80% vesting portion. During the three months ended March 31, 2023 and 2022, the Company recorded compensation expense, included in selling, general, and administrative, under the Profits Interests of $30,463 and zero, respectively. The Company uses the M onte Carlo Simulation model to estimate the fair value of Class D Incentive Units. Fair value is estimated at the date of grant for employee and nonemployee options. The following assumptions were used in the M onte Carlo Simulation model to calculate the fair value of Class D Incentive Units outstanding as of March 31, 2023. Class D Units Expected life of Class D Incentive Units (in years) (1) 5.5 Risk-free interest rate (2) 3.02 % Volatility (3) 69.50 % __________________ (1) The expected life of options is the average of the contractual term of the Class D Incentive Units and the vesting period. (2) The risk-free interest rate is based on the yields on U.S. Treasury debt securities with maturities approximating the estimated life of the options. (3) Volatility is estimated by management. As the Company has been a private company for most of its existence, there is not enough historical volatility data related to the Company’s Common stock as a public entity. Therefore, this estimate is based on the average volatility of certain public company peers within the Company’s industry. A summary of the status of the Company’s Class D Incentive Units as of December 31, 2022, and changes during the three months ended March 31, 2023, is presented below: Shares Weighted- Nonvested at December 31, 2022 250,000 13.28 Granted — — Vested — — Cancelled (1) 200,000 13.28 Nonvested and Outstanding at March 31, 2023 50,000 13.28 __________________ (1) Cancelled units represents unvested units granted to cliff vest on the grant anniversary date. However, the employees were terminated before the grant date anniversary. As a result, the previously recognized expenses of $421,371 was reversed. As of March 31, 2023, there was $367,848 of total unrecognized compensation cost related to nonvested Class D Incentive Units. The Company expects to recognize this compensation cost over a remaining weighted-average period of approximately 3.0 years.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events April 2023 Registered Direct Offering On April 14, 2023, the Company entered into a subscription agreement with a certain institutional and accredited investor, relating to the issuance and sale of 1,818,181 shares of common stock in a registered direct offering (the “April 2023 Offering”). The offering price for the shares was $0.55 per share of common stock. The closing of the April 2023 Offering occurred on April 17, 2023. The aggregate gross proceeds from the April 2023 Offering was approximately $1.0 million . Chardan Capital Markets LLC acted as the placement agent for the April 2023 Offering and received a sales commission of 6.0% of the gross proceeds. April 2023 ATM Offering Program

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying (i) unaudited condensed consolidated balance sheet as of December 31, 2022, which has been derived from audited financial statements, and (ii) unaudited interim condensed financial statements have been prepared in accordance pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Therefore, it is suggested that these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes in the 2022 Form 10-K, filed with the SEC on March 31, 2023. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, comprehensive loss, cash flows, and stockholders’ equity for the interim periods, but are not necessarily indicative of the results to be anticipated for the full year 2023 or any future period. In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the unaudited condensed consolidated financial statements are issued. Since inception, the Company has incurred recurring losses and negative cash flows from operations and has an accumulated deficit of $124.6 million as of March 31, 2023. Nuvve incurred operating losses of approximately $7.9 million as of the three months ended March 31, 2023, and $36.9 million and $27.2 million for the years ended December 31, 2022, and 2021, respectively. Nuvve cash used in operations were $5.8 million as of the three months ended March 31, 2023, and $34.1 million and $29.2 million for the years ended December 31, 2022, and 2021, respectively. As of March 31, 2023, Nuvve had a cash balance, working capital, and stockholders’ equity of $11.8 million, $19.4 million and $17.4 million, respectively. The Company continues to expect to generate operating losses and negative cash flows and may need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful expanded commercialization of the Company's Grid Integrated Vehicle ("GIVe") platform and the achievement of a level of revenues adequate to support its cost structure. Management plans to fund current operations through increased revenues and if required cash saving measures and or raising additional capital. Management's expectations with respect to the Company’s ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. There is an inherent risk that the Company may not achieve such financial projections and if so, cash outflows could be higher than currently anticipated. Should this occur, management plans to implement cash saving measures during this time period, including reductions in discretionary expenses related to consultants, travel, personnel, and personnel-related costs. If necessary, management believes it can raise additional capital through its at-the-market offering agreement. However, as such plans are not solely within management’s control management cannot conclude as of the date of this filing that the plans are probable of being successfully implemented and as such has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for twelve months from the date of issuance of our financial statements. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
Principles of Consolidation	Principles of ConsolidationThe condensed consolidated financial statements include the accounts and operations of the Company, its wholly owned subsidiaries and its consolidated variable interest entity. All intercompany accounts and transactions have been eliminated upon consolidation.
Variable Interest Entities	Variable Interest Entities Pursuant to the consolidation guidance, the Company first evaluates whether it holds a variable interest in an entity in which it has a financial relationship and, if so, whether or not that entity is a variable interest entity ("VIE"). A VIE is an entity with insufficient equity at risk for the entity to finance its activities without additional subordinated financial support or in which equity investors lack the characteristics of a controlling financial interest. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company concludes that it is the primary beneficiary and consolidates the VIE if the Company has both (i) the power to direct the activities of the VIE that most significantly influence the VIE's economic performance, and (ii) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. The Company formed Levo with Stonepeak and Evolve, in which the Company owns 51% of Levo's common units. The Company has determined that Levo is a VIE in which the Company is the primary beneficiary. Accordingly, the Company consolidates Levo and records a non-controlling interest for the share of the entity owned by Stonepeak and Evolve. Assets and Liabilities of Consolidated VIEs The Company's condensed consolidated financial statements include the assets, liabilities and results of operations of VIEs for which the Company is the primary beneficiary. The other equity holders’ interests are reflected in "Net income (loss) attributable to non-controlling interests" in the condensed consolidated statements of operations and "Non-controlling interests" in the condensed consolidated balance sheets. See Note 18 for details of non-controlling interests. The Company began consolidating the assets, liabilities and results of operations of Levo during the quarter ended September 30, 2021.
Noncontrolling Interest	Redeemable Non-Controlling Interest - Mezzanine Equity Redeemable non-controlling interest represents the shares of the preferred stock issued by Levo to Stonepeak and Evolve (the "preferred shareholders"), who own 49% of Levo common units. The preferred stock is not mandatorily redeemable or currently redeemable, but it could be redeemable with the passage of time at the election of Levo, the preferred shareholders or a triggering event as defined in the preferred stock agreement. As a result of the contingent put right available to the preferred shareholders, the redeemable non-controlling interests in Levo are classified as mezzanine equity in the Company’s unaudited condensed consolidated balance sheets. The initial carrying value of the redeemable non-controlling interest is reported at the initial proceeds received on issuance date, reduced by the fair value of embedded derivatives resulting in an adjusted initial carrying value. The adjusted initial carrying value is further adjusted for the accretion of the difference with the redemption price value using the effective interest method. The accretion amount is a deemed dividend recorded against retained earnings or, in its absence, to additional-paid-in-capital. The carrying amount of the redeemable non-controlling interest is measured at the higher of the carrying amount adjusted each reporting period for income (or loss) attributable to the non-controlling interest, or the carrying amount adjusted each reporting period by the accretion amount. See Note 18 for details. Non-controlling interests The Company presents non-controlling interests as a component of equity on its condensed consolidated balance sheets and reports the portion of its earnings or loss for non-controlling interest as net earnings or loss attributable to non-controlling interests in the condensed consolidated statements of operations. For entities that are consolidated, but not 100% owned, a portion of the net income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the net income or loss and corresponding equity that is not owned by the Company is included in non-controlling interests in the condensed consolidated financial statements. Non-controlling interests are presented outside as a separate component of stockholders’ equity on the Company’s condensed consolidated balance sheets. The primary components of non-controlling interests are separately presented in the Company’s condensed consolidated statements of changes in stockholders’ equity to clearly distinguish the interest in the Company and other ownership interests in the consolidated entities. Net income or loss includes the net income or loss attributable to the holders of non-controlling interests on the Company’s condensed consolidated statements of operations. Net income or loss is allocated to non-controlling interests in proportion to their relative ownership interests.
Emerging Growth Company	Emerging Growth CompanySection 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) permits emerging growth companies (“EGC”) to delay complying with new or revised financial accounting standards that do not yet apply to private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act). The Company qualifies as an EGC. The JOBS Act provides that an EGC can elect to opt-out of the extended transition period and comply with the requirements that apply to non-EGCs, but any such election to opt-out is irrevocable. The Company has elected not to opt-out of such an extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an EGC, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This different adoption timing may make a comparison of the Company’s financial statements with another public company, which is neither an EGC nor an EGC that has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include the impairment of intangible assets, the net realizable value of inventory, the fair value of share-based payments, lease incremental borrowing rate, derivative liability associated with redeemable preferred shares, revenue recognition, the fair value of warrants, and the recognition and disclosure of contingent liabilities. Management evaluates its estimates on an ongoing basis. Actual results could materially vary from those estimates.
Cash and Restricted Cash	Cash and Restricted Cash The Company maintains cash balances that can, at times, exceed amounts insured by the Federal Deposit Insurance Corporation, which is up to $250,000. The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area. In connection with a new office lease agreement, the Company was required to provide an irrevocable, unconditional letter of credit to the landlord upon execution of the lease. The amount securing the letter of credit was recorded as restricted cash as of March 31, 2023 and December 31, 2022 was $480,000 .
Concentrations of Credit Risk	Concentrations of Credit Risk At March 31, 2023 and December 31, 2022, the financial instruments which potentially expose the Company to concentration of credit risk consist of cash in financial institutions (in excess of federally insured limits) and trade receivables. The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable, as follows: For the three months ended March 31, 2023 one customer accounted for 58.9% of revenue. For the three months ended March 31, 2022 one customer in accounted for 72.8% o f revenue. During the three months ended March 31, 2023, the Company's top five customers accounted for approximately 76.5% o f the Company’s total revenue. During the three months ended March 31, 2022, the Company's top five customers accounted for approximately 87.5% o f the Company’s total revenue. At March 31, 2023 , one customer accounted f or 45.6% of accounts receivable. At December 31, 2022, three customers in aggregate accounted for 40.6% of a ccounts receivable. Approximat ely 69.2% and 53.6% of the Company’s trade accounts receivable balance was with five customers at March 31, 2023 and December 31, 2022 , respectively. The Company estimates its maximum credit risk for accounts receivable at the
Recently adopted accounting pronouncements/Recently issued accounting pronouncements not yet adopted	Recently adopted accounting pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires, among other things, the use of a new current expected credit loss ("CECL") model in determining the allowances for doubtful accounts with respect to accounts receivable, accrued straight-line rent receivable, and notes receivable. The CECL model requires that an entity estimate its lifetime expected credit loss with respect to these receivables and record allowances that, when deducted from the balance of the receivables, represent the net amounts expected to be collected. Entities will also be required to disclose information about how the entity developed the allowances, including changes in the factors that influenced its estimate of expected credit losses and the reasons for those changes. The Company adopted the guidance effective beginning January 1, 2023. The adoption of the guidance did not have a material impact on its condensed consolidated financial statements. Recently issued accounting pronouncements not yet adopted None applicable

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of assets and liabilities included in the company’s condensed consolidated balance sheets	The following table summarizes the carrying amounts of Levo assets and liabilities included in the Company’s condensed consolidated balance sheets at March 31, 2023: March 31, 2023 December 31, 2022 Assets Cash $ 27,505 $ 27,629 Prepaid expenses and other current assets 28,608 59,794 Total Assets $ 56,113 $ 87,423 Liabilities Accounts payable $ 6,000 $ 8,165 Accrued expenses and dividend payable 401,198 336,713 Derivative liability - non-controlling redeemable preferred shares 436,065 359,225 Total Liabilities $ 843,263 $ 704,103

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of information regarding disaggregated revenue based on revenue by service	The following table provides information regarding disaggregated revenue: Three Months Ended March 31, 2023 2022 Revenue recognized over time: Services $ 351,499 $ 194,650 Grants 74,401 117,249 Revenue recognized at point in time: Products 1,428,886 2,059,134 Total revenue $ 1,854,786 $ 2,371,033
Schedule of aggregate amount of revenue for the Company’s existing contracts with customers	The aggregate am ount of revenue for the Company’s existing contracts and grants with customers as of March 31, 2023 expected to be recognized in the future, and classified as deferred revenue on the condensed consolidated balance sheet, for year ended December 31, is as follows (this disclosure does not include revenue related to contracts whose original expected duration is one year or less): 2023 (remaining nine months) $ 177,132 Thereafter 1,005,960 Total $ 1,183,092
Schedule of company operates in a single business segment	The following table summarizes the Company’s revenues by geography: Three Months Ended March 31, 2023 2022 Revenues: United States $ 1,758,453 $ 2,227,734 United Kingdom 32,982 37,390 Denmark 63,351 105,909 $ 1,854,786 $ 2,371,033 The following table summarizes the Company’s intangible assets and property, plant and equipment in different geographic locations: March 31, December 31, Long-lived assets: United States $ 1,735,901 $ 1,795,267 United Kingdom 3,866 1,335 Denmark 174,518 181,982 $ 1,914,285 $ 1,978,584

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of liabilities measured at fair value on the condensed consolidated balance sheet	The following are the liabilities measured at fair value on the condensed consolidated balance sheet at March 31, 2023 and December 31, 2022 using quoted price in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3): Level 1: Level 2: Level 3: Total at March 31, Total Gains (Losses) For The Three Months Ended March 31, 2023 Recurring fair value measurements Private warrants $ — $ — $ 1,000 $ 1,000 $ 1,000 Stonepeak and Evolve unvested warrants $ — $ — $ — $ — $ — Institutional/Accredited Investor warrants $ — $ — $ 433,642 $ 433,642 $ (214,758) Derivative liability - non-controlling redeemable preferred shares $ — $ — $ 436,065 $ 436,065 $ (76,840) Total recurring fair value measurements $ — $ — $ 870,707 $ 870,707 $ (290,598) Level 1: Level 2: Level 3: Total at December 31, Total Gains (Losses) For The Three Months Ended March 31, 2022 Recurring fair value measurements Private warrants $ — $ — $ 2,000 $ 2,000 $ 433,000 Stonepeak and Evolve unvested warrants $ — $ — $ — $ — 4,343,000 Institutional/Accredited Investor warrants $ — $ — $ 218,884 $ 218,884 $ — Derivative liability - non-controlling redeemable preferred shares $ — $ — $ 359,225 $ 359,225 $ 53,472 Total recurring fair value measurements $ — $ — $ 580,109 $ 580,109 $ 4,829,472
Schedule of fair value on a recurring basis	The following is a reconciliation of the opening and closing balances for the liabilities related to the warrants (Note 11 ) and derivative liability - non-controlling redeemable preferred shares measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2023: Private warrants Stonepeak and Evolve unvested warrants Institutional/Accredited Investor warrants Non-controlling redeemable preferred shares - derivative liability Balance at December 31, 2022 $ 2,000 $ — $ 218,884 $ 359,225 Total (gains) losses for period included in earnings (1,000) — 214,758 76,840 Balance at March 31, 2023 $ 1,000 $ — 433,642 $ 436,065
Schedule of fair value measurement inputs and valuation techniques	The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve unvested warrants at March 31, 2023: Series C Unvested Warrants Series D Unvested Warrants Series E Unvested Warrants Series F Unvested Warrants Fair value (in millions) $— $— $— $— Valuation methodology Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Capital expenditure forecast (in millions) $— $— $— $— Probability of warrants vesting (a) —% —% —% —% __________________ (a) During the second quarter ended June 30, 2022, the Company significantly lowered its forecast of Levo's capital deployments due to the passage by the United States Congress of the Infrastructure Investment and Jobs Act bill, and the related unveiling of the Environmental Protection Agency’s 2022 Clean School Bus rebates. The resulting lower forecast of capital deployments reduced the probabilities of the future vesting of the unvested warrants. Therefore, at March 31, 2023, the Company has determined that it is unlikely that the unvested warrants will vest. The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve unvested warrants at March 31, 2022: Series C Unvested Warrants Series D Unvested Warrants Series E Unvested Warrants Series F Unvested Warrants Fair value (in millions) $1.7 $1.2 $0.8 $0.6 Valuation methodology Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Term (years) 9.10 9.10 9.10 9.10 Risk free rate 2.3% 2.3% 2.3% 2.3% Exercise price $15.0 $20.0 $30.0 $40.0 Volatility 56.0% 56.0% 56.0% 56.0% Capital expenditure forecast (in millions) $125.0 $250.0 $375.0 $500.0 Probability of warrants vesting 90.8% 76.0% 63.8% 54.4%

Derivative Liability - Non-Co_2

Derivative Liability - Non-Controlling Redeemable Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of derivative liabilities at fair value	The following table displays the fair value of derivatives by balance sheet line item: March 31, 2023 December 31, 2022 Derivative liability - non-controlling redeemable preferred shares $ 436,065 $ 359,225

Account Receivables, Net (Table

Account Receivables, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
Schedule of accounts receivable	The following tables summarizes the Company's accounts receivable: March 31, 2023 December 31, 2022 Trade receivables $ 2,609,724 $ 1,180,528 Less: allowance for credit losses (58,834) (58,834) Accounts receivable, net $ 2,550,890 $ 1,121,694 Allowance for doubtful accounts: Balance December 31, 2022 $ (58,834) Provision — Write-off — Recoveries — Balance March 31, 2023 $ (58,834)

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of inventory by category	The following table summarizes the Company’s inventories balance by category: March 31, 2023 December 31, 2022 DC Chargers $ 7,710,610 $ 9,248,398 AC Chargers 200,170 123,247 Vehicles - School Buses 1,620,000 1,620,000 Others 501,462 560,186 Total $ 10,032,242 $ 11,551,831

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	The following table summarizes the Company’s property, plant and equipment balance: Useful Lives March 31, 2023 December 31, 2022 Computers & Servers 1 year to 3 years $ 136,026 $ 130,417 Vehicles 5 years to 7 years 139,788 139,788 Office furniture and equipment 3 years to 5 years 332,161 326,613 Others (1) 5 years to 7 years 259,280 256,685 Total 867,255 853,503 Less: Accumulated Depreciation (259,751) (216,559) Property, plant and equipment, net $ 607,504 $ 636,944 March 31, 2023 March 31, 2022 Depreciation expense $ 49,958 $ 25,975 __________________

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of estimated future amortization expense amortizable intangible assets	Total estimated future amortization expense is as follows: 2023 (remaining nine months) $ 104,577 2024 139,437 2025 139,437 2026 137,770 2027 132,770 Thereafter 652,790 $ 1,306,781

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Schedule of common stock issuable upon exercise of warrants outstanding	The following table is a summary of the number of shares of the Company’s Common Stock issuable upon exercise of warrants outstanding at March 31, 2023: Number of Number of Number of Exercise Expiration Public Warrants 2,875,000 — 2,875,000 $11.50 March 19, 2026 Private Warrants 136,250 — 136,250 $11.50 March 19, 2026 PIPE Warrants 1,353,750 — 1,353,750 $11.50 March 19, 2026 Stonepeak/Evolve Warrants - series B 2,000,000 — 2,000,000 $10.00 May 17, 2031 Stonepeak/Evolve Warrants - series C 1,000,000 — 500,000 $15.00 May 17, 2031 Stonepeak/Evolve Warrants - series D 1,000,000 — 500,000 $20.00 May 17, 2031 Stonepeak/Evolve Warrants - series E 1,000,000 — 500,000 $30.00 May 17, 2031 Stonepeak/Evolve Warrants - series F 1,000,000 — 500,000 $40.00 May 17, 2031 Institutional/Accredited Investor Warrants 4,000,000 — 4,000,000 $3.75 July 29, 2027 14,365,000 12,365,000

Stock Option Plan (Tables)

Stock Option Plan (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense for stock options	Stock-based compensation expense recognized in selling, general, and administrative, and research and development are as follows: Three Months Ended March 31, 2023 2022 Options $ 682,948 $ 822,106 Restricted stock 596,161 613,839 Total $ 1,279,109 $ 1,435,945
Schedule of stock option activity	The following is a summary of the stock option activity under the 2010 Plan for the three months ended March 31, 2023: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2022 853,507 2.91 5.70 — Granted — — — — Exercised — — — — Forfeited (1,328) 2.11 — — Expired/Cancelled (14,601) 8.71 — — Outstanding - March 31, 2023 837,578 2.83 5.46 — Options Exercisable at March 31, 2023 796,154 2.54 4.22 — Option Vested at March 31, 2023 796,154 2.54 4.22 — The following is a summary of the stock option activity under the 2020 Plan for the three months ended March 31, 2023: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2022 1,711,112 11.71 8.46 — Granted — — — — Exercised — — — — Forfeited (10,575) 4.23 — — Expired/Cancelled (5,062) 11.96 — — Outstanding - March 31, 2023 1,695,475 11.75 8.22 — Options Exercisable at March 31, 2023 706,125 13.25 7.98 — Option Vested at March 31, 2023 706,125 13.25 7.98 — A summary of the status of the Company’s Class D Incentive Units as of December 31, 2022, and changes during the three months ended March 31, 2023, is presented below: Shares Weighted- Nonvested at December 31, 2022 250,000 13.28 Granted — — Vested — — Cancelled (1) 200,000 13.28 Nonvested and Outstanding at March 31, 2023 50,000 13.28 __________________
Disclosure of share-based compensation arrangements by share-based payment award	Other Information: Three Months Ended 2023 2022 Amount received from option exercised $ — $ — March 31, 2023 Weighted average remaining recognition period Total unrecognized options compensation costs $ 5,484,305 2.34
Schedule of nonvested restricted stock units	A summary of the status of the Company’s nonvested restricted stock units as of December 31, 2022, and changes during the three months ended March 31, 2023, is presented below: Shares Weighted- Nonvested at December 31, 2022 436,259 6.43 Granted 102,319 0.96 Vested/Release (139,259) 4.19 Cancelled/Forfeited — — Nonvested and Outstanding at March 31, 2023 399,319 5.81

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of income tax information	Three Months Ended March 31, 2023 2022 Income tax expense $ — $ — Effective tax rate 0.0 % 0.0 %

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of earnings per share	The following table sets forth the calculation of basic and diluted net loss per share attributable to common stockholders during the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 2022 Net loss attributable to Nuvve Holding Corp. common stockholders $ (7,897,151) $ (4,855,809) Weighted-average shares used to compute net loss per share attributable to Nuvve common stockholders, basic and diluted 24,596,181 18,864,374 Net Loss per share attributable to Nuvve common stockholders, basic and diluted $ (0.32) $ (0.26)
Schedule of antidilutive securities excluded from the computation of earnings per share	The following outstanding shares of common stock equivalents were excluded from the calculation of the diluted net loss per share attributable to Nuvve common stockholders because their effect would have been anti-dilutive: Three Months Ended March 31, 2023 2022 Stock options issued and outstanding 2,533,053 2,773,734 Nonvested restricted stock issued and outstanding 399,319 880,892 Public warrants 2,875,000 2,875,000 Private warrants 136,250 136,250 PIPE warrants 1,353,750 1,353,750 Stonepeak and Evolve warrants 6,000,000 6,000,000 Stonepeak and Evolve options 5,000,000 5,000,000 Institutional/Accredited Investor Warrants 4,000,000 — Total 22,297,372 19,019,626

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of Lease costs	Supplemental unaudited condensed consolidated balance sheet information related to leases is as follows: Classification March 31, 2023 December 31, 2022 Operating lease assets Right-of-use operating lease assets $ 5,192,320 5,305,881 Finance lease assets Property, plant and equipment, net 17,284 18,467 Total lease assets $ 5,209,604 $ 5,324,348 Operating lease liabilities - current Operating lease liabilities - current $ 850,821 824,326 Operating lease liabilities - noncurrent Operating lease liabilities - noncurrent 4,979,748 5,090,170 Finance lease liabilities - current Other liabilities 7,284 7,184 Finance lease liabilities - noncurrent Other long-term liabilities 11,818 12,959 Total lease liabilities $ 5,849,671 $ 5,934,639 The components of lease expense are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2023 2022 Operating lease expense Selling, general and administrative $ 228,633 $ 176,520 Finance lease expense: Amortization of finance lease assets Selling, general and administrative 1,423 5,940 Interest on finance lease liabilities Interest expense 493 639 Total lease expense $ 230,549 $ 183,099 Lease term and discount rate: March 31, 2023 December 31, 2022 Weighted-average remaining lease terms (in years): Operating lease 8.5 9.0 Finance lease 3.0 3.3 Weighted-average discount rate: Operating lease 7.8% 7.8% Finance lease 7.8% 7.8% Other Information: Three Months Ended March 31, Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows - operating leases $ 113,561 $ 62,269 Operating cash flows - finance leases $ 2,015 $ 639 Financing cash flows - finance leases $ 1,896 $ 2,073 Leased assets obtained in exchange for new finance lease liabilities $ 17,284 $ 23,550 Leased assets obtained in exchange for new operating lease liabilities $ — $ —
Schedule of lessee, operating lease, liability, maturity	Operating Lease Finance Lease Maturities of lease liabilities are as follows: March 31, 2023 March 31, 2023 2023 $ 661,418 $ 5,463 2024 892,212 7,284 2025 893,046 7,284 2026 921,273 1,821 2027 946,683 — Thereafter 3,798,554 — Total lease payments 8,113,186 21,852 Less: interest (2,282,617) (2,750) Total lease obligations $ 5,830,569 $ 19,102
Schedule of Finance lease, liability, maturity	Operating Lease Finance Lease Maturities of lease liabilities are as follows: March 31, 2023 March 31, 2023 2023 $ 661,418 $ 5,463 2024 892,212 7,284 2025 893,046 7,284 2026 921,273 1,821 2027 946,683 — Thereafter 3,798,554 — Total lease payments 8,113,186 21,852 Less: interest (2,282,617) (2,750) Total lease obligations $ 5,830,569 $ 19,102
Schedule of Sublease Income	Sublease income are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2023 2022 Sublease lease income Other, net $ 129,770 $ —
Schedule of lease income	Lease income are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2023 2022 Lease income Products and services $ 1,070 $ — Interest income Products and services 2,595 — Total lease income $ 3,665 $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of milestone event	Under the terms of the agreement, the Company will pay up to an aggregate $7,500,000 in royalties to the Seller upon achievement of milestones, related to the aggregate number of vehicles that have had access to the Company’s GIVe platform system for a period of at least six consecutive months, and for which the Company has received monetary consideration for such access pursuant to a subscription or other similar agreement with the vehicle’s owner as follows: Milestone Event: Aggregated Vehicles Milestone 10,000 $ 500,000 20,000 750,000 40,000 750,000 60,000 750,000 80,000 750,000 100,000 1,000,000 200,000 1,000,000 250,000 2,000,000 $ 7,500,000

Non-Controlling Interest (Table

Non-Controlling Interest (Tables)	3 Months Ended
	Mar. 31, 2023
Noncontrolling Interest [Abstract]
Schedule of preferred stock	At March 31, 2023, Series B Preferred Stock consisted of the following: Shares Authorized Shares Issued and Outstanding Stated Value per Share Initial Carrying Value Cumulative Unpaid Accrued Preferred Dividends Liquidation Preference 1,000,000 3,138 $ 1,000 $ 3,138,000 $ 395,898 $ 3,533,898
Schedule of condensed financial statements	The following table summarizes Levo non-controlling interests presented as a separate component of stockholders’ equity on the Company’s condensed consolidated balance sheet at March 31, 2023: March 31, 2023 December 31, 2022 Balance at December 31, 2022 $ (3,950,186) (2,501,633) Net income (loss) attributable to non-controlling interests $ 6,288 (538,841) Less: dividends paid to non-controlling interests 69,292 263,846 Less: Preferred share accretion adjustment 161,466 645,866 Non-controlling interests $ (4,174,656) $ (3,950,186)
Schedule of condensed income statement	The following table summarizes Levo non-controlling interests presented as a separate component of the Company’s condensed consolidated statements of operations as of March 31, 2023: Three Months Ended March 31, 2023 2022 Net income (loss) attributable to non-controlling interests $ 6,288 $ (100,933)
Schedule of redeemable noncontrolling interest	Redeemable Non-controlling Interest Reconciliation — Mezzanine Equity March 31, 2023 December 31, 2022 Beginning balance $ 3,547,765 $ 2,901,899 Preferred share Accretion adjustment 161,466 645,866 Ending balance $ 3,709,231 $ 3,547,765
Schedule of black-scholes option pricing model to estimate the fair value of stock options	The following assumptions were used in the M onte Carlo Simulation model to calculate the fair value of Class D Incentive Units outstanding as of March 31, 2023. Class D Units Expected life of Class D Incentive Units (in years) (1) 5.5 Risk-free interest rate (2) 3.02 % Volatility (3) 69.50 % __________________ (1) The expected life of options is the average of the contractual term of the Class D Incentive Units and the vesting period. (2) The risk-free interest rate is based on the yields on U.S. Treasury debt securities with maturities approximating the estimated life of the options. (3) Volatility is estimated by management. As the Company has been a private company for most of its existence, there is not enough historical volatility data related to the Company’s Common stock as a public entity. Therefore, this estimate is based on the average volatility of certain public company peers within the Company’s industry.
Schedule of stock option activity	The following is a summary of the stock option activity under the 2010 Plan for the three months ended March 31, 2023: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2022 853,507 2.91 5.70 — Granted — — — — Exercised — — — — Forfeited (1,328) 2.11 — — Expired/Cancelled (14,601) 8.71 — — Outstanding - March 31, 2023 837,578 2.83 5.46 — Options Exercisable at March 31, 2023 796,154 2.54 4.22 — Option Vested at March 31, 2023 796,154 2.54 4.22 — The following is a summary of the stock option activity under the 2020 Plan for the three months ended March 31, 2023: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2022 1,711,112 11.71 8.46 — Granted — — — — Exercised — — — — Forfeited (10,575) 4.23 — — Expired/Cancelled (5,062) 11.96 — — Outstanding - March 31, 2023 1,695,475 11.75 8.22 — Options Exercisable at March 31, 2023 706,125 13.25 7.98 — Option Vested at March 31, 2023 706,125 13.25 7.98 — A summary of the status of the Company’s Class D Incentive Units as of December 31, 2022, and changes during the three months ended March 31, 2023, is presented below: Shares Weighted- Nonvested at December 31, 2022 250,000 13.28 Granted — — Vested — — Cancelled (1) 200,000 13.28 Nonvested and Outstanding at March 31, 2023 50,000 13.28 __________________

Organization and Description _2

Organization and Description of Business (Details)	Mar. 31, 2023 subsidiary
Nuvve
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of wholly owned subsidiaries	2
Nuvve Corp.
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of wholly owned subsidiaries	4

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies [Line Items]
Accumulated deficit	$ (124,622,921)		$ (116,956,528)
Operating loss	(7,878,230)	$ (9,532,404)
Net loss	(7,660,105)	(4,731,261)	36,900,000	$ 27,200,000
Net cash used in operating activities	(5,831,702)	(8,449,889)	(34,100,000)	(29,200,000)
Cash	11,846,458		15,753,896
Working capital	19,400,000
Stockholders’ equity	17,384,371	$ 23,497,663	23,245,400	$ 27,012,445
FDIC amount	250,000
Restricted cash	$ 480,000		480,000
Levo Mobility LLC | Stonepeak
Summary of Significant Accounting Policies [Line Items]
Stonepeak and Evolve 49% ownership	49%
Variable Interest Entity | Levo Mobility LLC
Summary of Significant Accounting Policies [Line Items]
Cash	$ 27,505		$ 27,629
Variable interest entity	51%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) - Customer Concentration Risk	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue Benchmark | Customer 1
Revenue, Major Customer [Line Items]
Concentration risk	58.90%	72.80%
Revenue Benchmark | Top 5 Customers
Revenue, Major Customer [Line Items]
Concentration risk	76.50%	87.50%
Accounts Receivable | Customer 1
Revenue, Major Customer [Line Items]
Concentration risk	45.60%		40.60%
Accounts Receivable | Top 5 Customers
Revenue, Major Customer [Line Items]
Concentration risk	69.20%		53.60%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Assets and liabilities of consolidated VIEs (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Assets
Cash	$ 11,846,458	$ 15,753,896
Total Assets	36,367,425	41,199,590
Liabilities
Accounts payable	2,363,548	2,390,422
Accrued expenses	4,329,062	3,347,399
Derivative liability - non-controlling redeemable preferred shares	436,065	359,225
Total Liabilities	15,154,264	13,960,946
Variable Interest Entity | Levo Mobility LLC
Assets
Cash	27,505	27,629
Other current assets	28,608	59,794
Total Assets	56,113	87,423
Liabilities
Accounts payable	6,000	8,165
Accrued expenses	401,198	336,713
Derivative liability - non-controlling redeemable preferred shares	436,065	359,225
Total Liabilities	$ 843,263	$ 704,103

Revenue Recognition - Schedule

Revenue Recognition - Schedule of information regarding disaggregated revenue based on revenue by service (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Deferred Revenue Arrangement [Line Items]
Total revenue	$ 1,854,786	$ 2,371,033
Services
Deferred Revenue Arrangement [Line Items]
Total revenue	351,499	194,650
Grants
Deferred Revenue Arrangement [Line Items]
Total revenue	74,401	117,249
Products
Deferred Revenue Arrangement [Line Items]
Total revenue	$ 1,428,886	$ 2,059,134

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of aggregate amount of revenue for the Company’s existing contracts with customers (Details)	Mar. 31, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 1,183,092
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 177,132
Revenue, remaining performance obligation, expected timing of satisfaction, period	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 1,005,960
Revenue, remaining performance obligation, expected timing of satisfaction, period

Revenue Recognition - Schedul_3

Revenue Recognition - Schedule of segment reporting (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenues	$ 1,854,786	$ 2,371,033
Long-lived assets	1,914,285		$ 1,978,584
United States
Segment Reporting Information [Line Items]
Revenues	1,758,453	2,227,734
Long-lived assets	1,735,901		1,795,267
United Kingdom
Segment Reporting Information [Line Items]
Revenues	32,982	37,390
Long-lived assets	3,866		1,335
Denmark
Segment Reporting Information [Line Items]
Revenues	63,351	$ 105,909
Long-lived assets	$ 174,518		$ 181,982

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of liabilities measured at fair value on the condensed consolidated balance sheet (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Recurring fair value measurements
Total recurring fair value measurements	$ 870,707		$ 580,109
Recurring fair value measurements, gain (loss) during period	(290,598)	$ 4,829,472
Derivative liability - non-controlling redeemable preferred shares
Recurring fair value measurements
Total recurring fair value measurements	436,065		359,225
Recurring fair value measurements, gain (loss) during period	(76,840)	53,472
Private warrants
Recurring fair value measurements
Total recurring fair value measurements	1,000		2,000
Recurring fair value measurements, gain (loss) during period	1,000	433,000
Stonepeak and Evolve unvested warrants
Recurring fair value measurements
Total recurring fair value measurements	0		0
Recurring fair value measurements, gain (loss) during period	0	4,343,000
Institutional/Accredited Investor warrants
Recurring fair value measurements
Total recurring fair value measurements	433,642		218,884
Recurring fair value measurements, gain (loss) during period	(214,758)	$ 0
Level 1: Quoted Prices in Active Markets for Identical Assets
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 1: Quoted Prices in Active Markets for Identical Assets | Derivative liability - non-controlling redeemable preferred shares
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 1: Quoted Prices in Active Markets for Identical Assets | Private warrants
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 1: Quoted Prices in Active Markets for Identical Assets | Stonepeak and Evolve unvested warrants
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 1: Quoted Prices in Active Markets for Identical Assets | Institutional/Accredited Investor warrants
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 2: Significant Other Observable Inputs
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 2: Significant Other Observable Inputs | Derivative liability - non-controlling redeemable preferred shares
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 2: Significant Other Observable Inputs | Private warrants
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 2: Significant Other Observable Inputs | Stonepeak and Evolve unvested warrants
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 2: Significant Other Observable Inputs | Institutional/Accredited Investor warrants
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 3: Significant Unobservable Inputs
Recurring fair value measurements
Total recurring fair value measurements	870,707		580,109
Level 3: Significant Unobservable Inputs | Derivative liability - non-controlling redeemable preferred shares
Recurring fair value measurements
Total recurring fair value measurements	436,065		359,225
Level 3: Significant Unobservable Inputs | Private warrants
Recurring fair value measurements
Total recurring fair value measurements	1,000		2,000
Level 3: Significant Unobservable Inputs | Stonepeak and Evolve unvested warrants
Recurring fair value measurements
Total recurring fair value measurements	0		0
Level 3: Significant Unobservable Inputs | Institutional/Accredited Investor warrants
Recurring fair value measurements
Total recurring fair value measurements	$ 433,642		$ 218,884

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of fair value on a recurring basis (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Non-controlling redeemable preferred shares - derivative liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ 359,225
Total (gains) losses for period included in earnings	76,840
Balance	436,065
Private warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	2,000
Total (gains) losses for period included in earnings	(1,000)
Balance	1,000
Stonepeak and Evolve unvested warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	0
Total (gains) losses for period included in earnings	0
Balance	0
Institutional/Accredited Investor warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	218,884
Balance	$ 433,642

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details)	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares	Mar. 31, 2022 $ / shares	May 17, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, term				10 years
Private Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share)	$ 11.50
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives, term	1 year 4 months 2 days		3 years
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives, term	7 years		7 years
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.036		0.024
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.650		0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Probability Of Redemption Trigger
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.750		0.750
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, term	2 years 11 months 19 days		3 years 2 months 19 days
Exercise price (in Dollars per share)	$ 11.50		$ 11.50
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.0382		0.0420
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.620		0.670
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Institutional/Accredited Investor warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, term	4 years 9 months 18 days	5 years 1 month 6 days
Exercise price (in Dollars per share)	$ 3.75	$ 3.75
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Institutional/Accredited Investor warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.0362	0.0397
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Institutional/Accredited Investor warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.640	0.620
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Institutional/Accredited Investor warrants | Measurement Input, Common Stock Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share)	$ 0.70	$ 0.50

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Techniques (Details)	Mar. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($) $ / shares	May 17, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 870,707	$ 580,109
Warrants outstanding, term				10 years
Series C Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 15
Series D Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share) | $ / shares	20
Series E Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share) | $ / shares	30
Series F Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 40
Level 3: Significant Unobservable Inputs
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 870,707	$ 580,109
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series C Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	0		$ 1,700,000
Warrants outstanding, term			9 years 1 month 6 days
Exercise price (in Dollars per share) | $ / shares			$ 15
Capital expenditure forecast (in millions)	$ 0		$ 125,000,000
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series C Unvested Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input			0.023
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series C Unvested Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input			0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series C Unvested Warrants | Measurement input, probability of warrants vesting
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0		0.908
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series D Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 0		$ 1,200,000
Warrants outstanding, term			9 years 1 month 6 days
Exercise price (in Dollars per share) | $ / shares			$ 20
Capital expenditure forecast (in millions)	$ 0		$ 250,000,000
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series D Unvested Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input			0.023
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series D Unvested Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input			0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series D Unvested Warrants | Measurement input, probability of warrants vesting
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0		0.760
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series E Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 0		$ 800,000
Warrants outstanding, term			9 years 1 month 6 days
Exercise price (in Dollars per share) | $ / shares			$ 30
Capital expenditure forecast (in millions)	$ 0		$ 375,000,000
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series E Unvested Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input			0.023
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series E Unvested Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input			0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series E Unvested Warrants | Measurement input, probability of warrants vesting
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0		0.638
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series F Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 0		$ 600,000
Warrants outstanding, term			9 years 1 month 6 days
Exercise price (in Dollars per share) | $ / shares			$ 40
Capital expenditure forecast (in millions)	$ 0		$ 500,000,000
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series F Unvested Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input			0.023
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series F Unvested Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input			0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series F Unvested Warrants | Measurement input, probability of warrants vesting
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0		0.544

Derivative Liability - Non-Co_3

Derivative Liability - Non-Controlling Redeemable Preferred Stock (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Embedded Derivative [Line Items]
Derivative liability - non-controlling redeemable preferred shares	$ 436,065	$ 359,225
Other Long-term Liabilities
Embedded Derivative [Line Items]
Derivative liability - non-controlling redeemable preferred shares	$ 436,065	$ 359,225

Investments (Details)

Investments (Details) - USD ($)		3 Months Ended
	Mar. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Jun. 06, 2022
Schedule of Equity Method Investments [Line Items]
Consulting services (in Dollars)		$ 0	$ 0
Proceeds from sale of investments in equity securities		1,325,155	0
Gains from sale of investments in equity securities		$ 325,155	$ 0
Dreev
Schedule of Equity Method Investments [Line Items]
Company's equity ownership		13%
Switch EV
Schedule of Equity Method Investments [Line Items]
Company's equity ownership				5%
Equity method investments				$ 1,000,000
Proceeds from sale of investments in equity securities	$ 1,300,000
Gains from sale of investments in equity securities	$ 300,000

Account Receivables, Net (Detai

Account Receivables, Net (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Less: allowance for credit losses	$ (58,834)	$ (58,834)
Accounts receivable, net	2,550,890	1,121,694
Allowance for doubtful accounts:
Balance December 31, 2022	(58,834)
Provision	0
Write-off	0
Recoveries	0
Balance March 31, 2023	(58,834)
Trade Accounts Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Trade receivables	$ 2,609,724	$ 1,180,528

Inventories (Details)

Inventories (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Inventory [Line Items]
Inventory, gross	$ 10,032,242	$ 11,551,831
DC Chargers
Inventory [Line Items]
Inventory, gross	7,710,610	9,248,398
AC Chargers
Inventory [Line Items]
Inventory, gross	200,170	123,247
Vehicles - School Buses
Inventory [Line Items]
Inventory, gross	1,620,000	1,620,000
Others
Inventory [Line Items]
Inventory, gross	$ 501,462	$ 560,186

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 867,255		$ 853,503
Less: Accumulated Depreciation	(259,751)		(216,559)
Property, plant and equipment, net	607,504		636,944
Depreciation expense	49,958	$ 25,975
Computers & Servers
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 136,026		130,417
Computers & Servers | Minimum
Property, Plant and Equipment [Line Items]
Useful lives	1 year
Computers & Servers | Maximum
Property, Plant and Equipment [Line Items]
Useful lives	3 years
Vehicles
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 139,788		139,788
Vehicles | Minimum
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Vehicles | Maximum
Property, Plant and Equipment [Line Items]
Useful lives	7 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 332,161		326,613
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful lives	3 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Others
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 259,280		$ 256,685
Others | Minimum
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Others | Maximum
Property, Plant and Equipment [Line Items]
Useful lives	7 years

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Gross intangible asset	$ 2,091,556		$ 2,091,556
Amortization expense of intangible assets	34,859	$ 34,859
Finite-lived intangible assets, accumulated amortization	784,775		$ 749,916
Finite-lived intangible assets, net	$ 1,306,781
Acquire finite-lived intangible assets, weighted average useful life	9 years 7 months 6 days

Intangible Assets - Schedule of

Intangible Assets - Schedule of estimated future amortization expense amortizable intangible assets (Details)	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (remaining nine months)	$ 104,577
2024	139,437
2025	139,437
2026	137,770
2027	132,770
Thereafter	652,790
Total estimated future amortization expense	$ 1,306,781

Stockholders_ Equity (Details)

Stockholders’ Equity (Details)								3 Months Ended
	Feb. 17, 2023 USD ($) $ / shares shares	Jan. 31, 2023 USD ($)	Jul. 27, 2022 USD ($) $ / shares shares	Apr. 25, 2022 USD ($)	May 17, 2021 USD ($) $ / shares shares	Nov. 11, 2020 USD ($) $ / shares shares	Feb. 19, 2020 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) class_of_stock $ / shares shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 $ / shares shares
Stockholders' Equity [Line Items]
Number of classes of stock | class_of_stock								2
Authorized capital stock (in Shares)								101,000,000
Common stock, shares authorized								100,000,000		100,000,000
Common stock par value (in Dollars per share) | $ / shares								$ 0.0001		$ 0.0001
Preferred stock, shares authorized								1,000,000
Preferred stock par value (in Dollars per share) | $ / shares								$ 0.0001
Amount of purchase | $			$ 14,000,000
Sale price (in Dollars per share) | $ / shares					$ 50
Proceeds from common stock offering, net of offering costs | $								$ 136,717	$ 0
Net proceeds from offering | $			$ 13,100,000
Warrants outstanding, term					10 years
Purchase agreement, authorized amount | $					$ 250,000,000
Grant date fair value of securities purchase agreement | $					$ 12,600,000
Unit Purchase Option
Stockholders' Equity [Line Items]
Shares issued (in Dollars per share) | $ / shares							$ 100
Exercisable units (in shares)							316,250
Options exercisable (in Dollars per share) | $ / shares							$ 11.50
Aggregate exercise price | $							$ 3,636,875
Number of shares included in a unit (in shares)							1.1
Unit Purchase Option | Minimum
Stockholders' Equity [Line Items]
Right to registration, period							5 years
Unit Purchase Option | Maximum
Stockholders' Equity [Line Items]
Right to registration, period							7 years
Investor
Stockholders' Equity [Line Items]
Common stock shares purchase (in Shares)						1,425,000
Purchase price per share value (in Dollars per share) | $ / shares						$ 10
PIPE
Stockholders' Equity [Line Items]
Sale of units (in Shares)						1.9
Sale price (in Dollars per share) | $ / shares						$ 11.50
Aggregate purchase price of common stock (in Dollars) | $						$ 14,250,000
Stonepeak/Evolve Warrants - series B
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares)					2,000,000
Exercise price (in Dollars per share) | $ / shares					$ 10
Stonepeak/Evolve Warrants - series C
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares)					1,000,000
Exercise price (in Dollars per share) | $ / shares					$ 15
Percent of warrants vested upon issuance					50%
Percent of warrants vested upon additional capital expenditures					50%
Additional capital expenditure to trigger exercise of nonvested warrants | $					$ 125,000,000
Stonepeak/Evolve Warrants - series D
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares)					1,000,000
Exercise price (in Dollars per share) | $ / shares					$ 20
Percent of warrants vested upon issuance					50%
Percent of warrants vested upon additional capital expenditures					50%
Additional capital expenditure to trigger exercise of nonvested warrants | $					$ 250,000,000
Stonepeak/Evolve Warrants - series E
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares)					1,000,000
Exercise price (in Dollars per share) | $ / shares					$ 30
Percent of warrants vested upon issuance					50%
Percent of warrants vested upon additional capital expenditures					50%
Additional capital expenditure to trigger exercise of nonvested warrants | $					$ 375,000,000
Stonepeak/Evolve Warrants - series F
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares)					1,000,000
Exercise price (in Dollars per share) | $ / shares					$ 40
Percent of warrants vested upon issuance					50%
Percent of warrants vested upon additional capital expenditures					50%
Additional capital expenditure to trigger exercise of nonvested warrants | $					$ 500,000,000
Option vesting period					180 days
Stonepeak
Stockholders' Equity [Line Items]
Percent of warrants issued					90%
Evolve
Stockholders' Equity [Line Items]
Percent of warrants issued					10%
Common Stock
Stockholders' Equity [Line Items]
Common stock par value (in Dollars per share) | $ / shares			$ 0.0001
Sale of units (in Shares)			2,150,000
Prefunded Warrant
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares)			1,850,000
Class of warrant or right, number of securities called by each warrant			1
Warrants or rights exercisable term			5 years
Warrants
Stockholders' Equity [Line Items]
Sale of units (in Shares)							5,750,000
Number of securities called by warrants (in shares)			4,000,000
Exercise price (in Dollars per share) | $ / shares			$ 3.75
Stonepeak/Evolve Warrants - series B
Stockholders' Equity [Line Items]
Exercise price (in Dollars per share) | $ / shares								$ 10
Warrants outstanding, grant date fair value | $					$ 12,800,000
Stonepeak/Evolve Warrants - series C
Stockholders' Equity [Line Items]
Exercise price (in Dollars per share) | $ / shares								15
Warrants outstanding, grant date fair value | $					5,600,000
Stonepeak/Evolve Warrants - series D
Stockholders' Equity [Line Items]
Exercise price (in Dollars per share) | $ / shares								20
Warrants outstanding, grant date fair value | $					4,800,000
Stonepeak/Evolve Warrants - series E
Stockholders' Equity [Line Items]
Exercise price (in Dollars per share) | $ / shares								30
Warrants outstanding, grant date fair value | $					3,800,000
Stonepeak/Evolve Warrants - series F
Stockholders' Equity [Line Items]
Exercise price (in Dollars per share) | $ / shares								$ 40
Warrants outstanding, grant date fair value | $					$ 3,200,000
Stonepeak Warrants | Securities Purchase Agreement
Stockholders' Equity [Line Items]
Percent of warrants issued					90%
Evolve Warrants | Securities Purchase Agreement
Stockholders' Equity [Line Items]
Percent of warrants issued					10%
Shelf Registration
Stockholders' Equity [Line Items]
Amount of purchase | $				$ 100,000,000
At The Market Offering
Stockholders' Equity [Line Items]
Amount of purchase | $		$ 25,000,000
Agent fee percentage		3%
Placement agent fee, reimbursement amount | $		$ 50,000
Sale of units (in Shares)								78,638
Sale price (in Dollars per share) | $ / shares								$ 1.79
Proceeds from common stock offering, net of offering costs | $								$ 100,000
Registered Direct Offering
Stockholders' Equity [Line Items]
Agent fee percentage	6%
Proceeds from common stock offering, net of offering costs | $	$ 500,000
Per unit price (in Dollars per share) | $ / shares	$ 0.92
Registered Direct Offering | Common Stock
Stockholders' Equity [Line Items]
Sale of units (in Shares)	543,478
IPO | Newborn
Stockholders' Equity [Line Items]
Class of warrant or right, number of securities called by each warrant							1
Number of warrants per unit (in Shares)							1
Percent of one share of common stock							50%
Private Placement | Newborn
Stockholders' Equity [Line Items]
Number of warrants per unit (in Shares)							1
Private Placement | Warrants
Stockholders' Equity [Line Items]
Aggregate share purchase (in Shares)							272,500

Stockholders_ Equity - Schedule

Stockholders’ Equity - Schedule of common stock issuable upon exercise of warrants outstanding (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	14,365,000
Number of Warrants Exercisable (in shares)	12,365,000
Public Warrants
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	2,875,000
Number of Warrants Exercised (in shares)	0
Number of Warrants Exercisable (in shares)	2,875,000
Exercise price (in Dollars per share) | $ / shares	$ 11.50
Private Warrants
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	136,250
Number of Warrants Exercised (in shares)	0
Number of Warrants Exercisable (in shares)	136,250
Exercise price (in Dollars per share) | $ / shares	$ 11.50
PIPE Warrants
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,353,750
Number of Warrants Exercised (in shares)	0
Number of Warrants Exercisable (in shares)	1,353,750
Exercise price (in Dollars per share) | $ / shares	$ 11.50
Stonepeak/Evolve Warrants - series B
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	2,000,000
Number of Warrants Exercised (in shares)	0
Number of Warrants Exercisable (in shares)	2,000,000
Exercise price (in Dollars per share) | $ / shares	$ 10
Stonepeak/Evolve Warrants - series C
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,000,000
Number of Warrants Exercised (in shares)	0
Number of Warrants Exercisable (in shares)	500,000
Exercise price (in Dollars per share) | $ / shares	$ 15
Stonepeak/Evolve Warrants - series D
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,000,000
Number of Warrants Exercised (in shares)	0
Number of Warrants Exercisable (in shares)	500,000
Exercise price (in Dollars per share) | $ / shares	$ 20
Stonepeak/Evolve Warrants - series E
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,000,000
Number of Warrants Exercised (in shares)	0
Number of Warrants Exercisable (in shares)	500,000
Exercise price (in Dollars per share) | $ / shares	$ 30
Stonepeak/Evolve Warrants - series F
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,000,000
Number of Warrants Exercised (in shares)	0
Number of Warrants Exercisable (in shares)	500,000
Exercise price (in Dollars per share) | $ / shares	$ 40
Institutional/Accredited Investor Warrants
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	4,000,000
Number of Warrants Exercised (in shares)	0
Number of Warrants Exercisable (in shares)	4,000,000
Exercise price (in Dollars per share) | $ / shares	$ 3.75

Stock Option Plan - Narrative (

Stock Option Plan - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based option modified (in Shares)			1,640,000
Increase decrease exercise price (in Dollars per share)			$ 0.60
Incremental compensation cost (in Dollars)			$ 246,000
Weighted average remaining recognition period	2 years 4 months 2 days
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional compensation expense	$ 12,632	$ 19,699
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to nonvested restricted stock	$ 1,365,948
Weighted average remaining recognition period	9 months 7 days
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate of common shares (in Shares)	3,300,000
Option contractual life	10 years
Issuance of common stock available for future (in Shares)	677,176
Weighted average grant date fair value of options granted during period (in Dollars per share)	$ 0
2020 Plan | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting period	4 years
2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options granted during period (in Dollars per share)	$ 0

Stock Option Plan - Schedule of

Stock Option Plan - Schedule of stock-based compensation expense for stock options (Details) - Selling, general and administrative - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 682,948	$ 822,106
Restricted stock
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	596,161	613,839
Options and Restricted Stock
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 1,279,109	$ 1,435,945

Stock Option Plan - Schedule _2

Stock Option Plan - Schedule of stock option activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
2010 Plan
Shares
Beginning balance (in Shares)	853,507
Granted, (in Shares)	0
Exercised (in Shares)	0
Forfeited (in Shares)	(1,328)
Expired/Cancelled (in Shares)	(14,601)
Ending balance (in Shares)	837,578	853,507
Options exercisable (in Shares)	796,154
Options vested (in Shares)	796,154
Weighted- Average Exercise Price per Share($)
Beginning balance (in Dollars per share)	$ 2.91
Granted (in Dollars per share)	0
Exercised (in Dollars per share)	0
Forfeited (in Dollars per share)	2.11
Expired/Cancelled (in Dollars per share)	8.71
Ending balance (in Dollars per share)	2.83	$ 2.91
Options exercisable (in Dollars per share)	2.54
Options vested (in Dollars per share)	$ 2.54
Weighted- Average Remaining Contractual Term (Years)
Outstanding, weighted-average remaining contractual term	5 years 5 months 15 days	5 years 8 months 12 days
Options exercisable, weighted average remaining contractual term	4 years 2 months 19 days
Options vested, weighted average remaining contractual term	4 years 2 months 19 days
Aggregate Intrinsic Value($)
Outstanding	$ 0	$ 0
Exercisable	0
Vested	$ 0
2020 Plan
Shares
Beginning balance (in Shares)	1,711,112
Granted, (in Shares)	0
Exercised (in Shares)	0
Forfeited (in Shares)	(10,575)
Expired/Cancelled (in Shares)	(5,062)
Ending balance (in Shares)	1,695,475	1,711,112
Options exercisable (in Shares)	706,125
Options vested (in Shares)	706,125
Weighted- Average Exercise Price per Share($)
Beginning balance (in Dollars per share)	$ 11.71
Granted (in Dollars per share)	0
Exercised (in Dollars per share)	0
Forfeited (in Dollars per share)	4.23
Expired/Cancelled (in Dollars per share)	11.96
Ending balance (in Dollars per share)	11.75	$ 11.71
Options exercisable (in Dollars per share)	13.25
Options vested (in Dollars per share)	$ 13.25
Weighted- Average Remaining Contractual Term (Years)
Outstanding, weighted-average remaining contractual term	8 years 2 months 19 days	8 years 5 months 15 days
Options exercisable, weighted average remaining contractual term	7 years 11 months 23 days
Options vested, weighted average remaining contractual term	7 years 11 months 23 days
Aggregate Intrinsic Value($)
Outstanding	$ 0	$ 0
Exercisable	0
Vested	$ 0

Stock Option Plan - Schedule _3

Stock Option Plan - Schedule of other share based compensation information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Amount received from option exercised	$ 0	$ 0
Total unrecognized options compensation costs	$ 5,484,305
Weighted average remaining recognition period	2 years 4 months 2 days

Stock Option Plan - Schedule _4

Stock Option Plan - Schedule of nonvested restricted stock units (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Shares
Beginning balance (in Shares) | shares	436,259
Granted (in Shares) | shares	102,319
Vested/Release (in Shares) | shares	(139,259)
Cancelled/Forfeited (in Shares) | shares	0
Ending balance (in Shares) | shares	399,319
Weighted- Average Grant Date Fair Value($)
Beginning balance (in Dollars per share) | $ / shares	$ 6.43
Granted (in Dollars per share) | $ / shares	0.96
Vested/Release (in Dollars per share) | $ / shares	4.19
Cancelled/Forfeited (in Dollars per share) | $ / shares	0
Ending balance (in Dollars per share) | $ / shares	$ 5.81

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0
Effective tax rate	0%	0%

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net loss attributable to Nuvve Holding Corp. common stockholders, basic	$ (7,897,151)	$ (4,855,809)
Net loss attributable to Nuvve Holding Corp. common stockholders, diluted	$ (7,897,151)	$ (4,855,809)
Weighted-average shares used in computing net loss per share attributable to Nuvve Holding Corp. common stockholders, basic (in Shares)	24,596,181	18,864,374
Weighted-average shares used in computing net loss per share attributable to Nuvve Holding Corp. common stockholders, diluted (in Shares)	24,596,181	18,864,374
Net Loss per share attributable to Nuvve common stockholders, basic (in Dollars per share)	$ (0.32)	$ (0.26)
Net Loss per share attributable to Nuvve common stockholders, diluted (in Dollars per share)	$ (0.32)	$ (0.26)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Attributable to Nuvve common stockholders (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	22,297,372	19,019,626
Stock options issued and outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	2,533,053	2,773,734
Nonvested restricted stock issued and outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	399,319	880,892
Public warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	2,875,000	2,875,000
Private warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	136,250	136,250
PIPE warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	1,353,750	1,353,750
Stonepeak and Evolve warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	6,000,000	6,000,000
Stonepeak and Evolve options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	5,000,000	5,000,000
Institutional/Accredited Investor Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	4,000,000	0

Related Parties (Details)

Related Parties (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Related Party Transactions [Abstract]
Revenue from related parties	$ 65,670	$ 28,000
Accounts receivable, related parties	$ 0		$ 0

Leases - Lease cost (Details)

Leases - Lease cost (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Right-of-use operating lease assets	$ 5,192,320		$ 5,305,881
Finance lease assets	17,284		18,467
Operating and finance lease right-of-use assets	$ 5,209,604		5,324,348
Finance lease, right-of-use asset, statement of financial position [extensible list]	Property and equipment, net
Operating lease liabilities - current	$ 850,821		824,326
Operating lease liabilities - noncurrent	4,979,748		5,090,170
Finance lease liabilities - current	7,284		7,184
Finance lease liabilities - noncurrent	11,818		12,959
Total lease obligations	$ 5,849,671		$ 5,934,639
Operating lease, liability, noncurrent, statement of financial position, extensible list	Operating lease liabilities - noncurrent
Finance lease, liability, current, statement of financial position, extensible list	Other liabilities
Finance lease, liability, noncurrent, statement of financial position, extensible list	Other long-term liabilities
Total lease expense	$ 230,549	$ 183,099
Selling, general and administrative
Lessee, Lease, Description [Line Items]
Operating lease expense	228,633	176,520
Amortization of finance lease assets	1,423	5,940
Interest expense
Lessee, Lease, Description [Line Items]
Interest expense	$ 493	$ 639

Leases - Schedule of operating

Leases - Schedule of operating lease liability maturity (Details)	Mar. 31, 2023 USD ($)
Operating Lease
2023	$ 661,418
2024	892,212
2025	893,046
2026	921,273
2027	946,683
Thereafter	3,798,554
Total lease payments	8,113,186
Less: interest	(2,282,617)
Total lease obligations	5,830,569
Finance Lease
2023	5,463
2024	7,284
2025	7,284
2026	1,821
2027	0
Thereafter	0
Total lease payments	21,852
Less: interest	(2,750)
Total lease obligations	$ 19,102

Leases - Lease term, discount r

Leases - Lease term, discount rate, and other information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Weighted-average remaining lease terms (in years):
Operating lease	8 years 6 months		9 years
Finance lease	3 years		3 years 3 months 18 days
Weighted-average discount rate:
Operating lease	7.80%		7.80%
Finance lease	7.80%		7.80%
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows - operating leases	$ 113,561	$ 62,269
Operating cash flows - finance leases	2,015	639
Financing cash flows - finance leases	1,896	2,073
Leased assets obtained in exchange for new finance lease liabilities	17,284	23,550
Leased assets obtained in exchange for new operating lease liabilities	$ 0	$ 0

Leases - Sublease (Details)

Leases - Sublease (Details)	1 Months Ended	3 Months Ended
	Apr. 30, 2022 USD ($) ft²	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Net area subleased | ft²	4,811
Minimum
Lessee, Lease, Description [Line Items]
Sublease term	6 months
Sublease monthly rental income	$ 2,250
Maximum
Lessee, Lease, Description [Line Items]
Sublease term	12 months
Sublease monthly rental income	$ 14,500
Other, net
Lessee, Lease, Description [Line Items]
Sublease lease income		$ 129,770	$ 0

Leases - Lessor (Details)

Leases - Lessor (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Feb. 28, 2022
Lessee, Lease, Description [Line Items]
Investment in leases	$ 95,250	$ 0	$ 97,054
Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]	Total revenue
Master Services Agreement
Lessee, Lease, Description [Line Items]
Lease term (in years)				10 years
Lease income	$ 1,070	0
Interest income	2,595	0
Total lease income	$ 3,665	$ 0

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 31, 2022	Nov. 30, 2017	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Nov. 02, 2022	Mar. 31, 2022	Jul. 20, 2021	Sep. 01, 2016
Other Commitments [Line Items]
Installment amount			$ 133,333				$ 100,000		$ 400,000
Research agreement, renewal period	1 year
Related party debt outstanding			$ 166,667
Property expire			20 years
Royalty expense, aggregate amount under agreement			$ 700,000
Royalty expense			0	$ 0
Acquisition costs, amortization period		15 years
Investment			$ 270,000
Purchase obligation								$ 13,200,000
Purchase obligation, purchases					$ 6,300,000
Disputed amount for V2G Chargers						$ 5,000,000
IP Acquisition Agreement
Other Commitments [Line Items]
Asset acquisition, upfront payment		$ 500,000
Asset acquisition, equity consideration transferred		1,491,556
Asset acquisition, consideration transferred		1,991,556
Royalties payments		$ 7,500,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of milestone event (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Other Commitments [Line Items]
Milestone payment amount	$ 7,500,000
10000
Other Commitments [Line Items]
Milestone payment amount	500,000
20000
Other Commitments [Line Items]
Milestone payment amount	750,000
40000
Other Commitments [Line Items]
Milestone payment amount	750,000
60000
Other Commitments [Line Items]
Milestone payment amount	750,000
80000
Other Commitments [Line Items]
Milestone payment amount	750,000
100000
Other Commitments [Line Items]
Milestone payment amount	1,000,000
200000
Other Commitments [Line Items]
Milestone payment amount	1,000,000
250000
Other Commitments [Line Items]
Milestone payment amount	$ 2,000,000

Non-Controlling Interest - Narr

Non-Controlling Interest - Narrative (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($) vesting_installment $ / shares shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)
Noncontrolling Interest [Line Items]
Temporary equity, shares authorized (in Shares) | shares	1,000,000		1,000,000
Temporary equity, par value (in Dollars per share) | $ / shares	$ 0		$ 0
Temporary equity, shares issued (in Shares) | shares	3,138		3,138
Temporary equity, shares outstanding (in Shares) | shares	3,138		3,138
Decrease to redeemable noncontrolling interest	$ 497,606
Redeemable noncontrolling interest, equity, carrying amount	$ 2,640,394
Accretion period (in years)	7 years
Weighted average remaining recognition period	2 years 4 months 2 days
Class D Incentive Units
Noncontrolling Interest [Line Items]
Vesting percentage	80%
Number of vesting installments | vesting_installment	4
Percentage of incentive units to be vested	20%
Total unrecognized compensation cost related to nonvested restricted stock	$ 367,848
Weighted average remaining recognition period	3 years
Class D Incentive Units | Selling, general and administrative
Noncontrolling Interest [Line Items]
Stock-based compensation	$ 30,463	$ 0
Class D Incentive Units | Share-Based Payment Arrangement, All Tranches
Noncontrolling Interest [Line Items]
Vesting percentage	80%
Class D Incentive Units | Share Based Arrangement Tranche Four
Noncontrolling Interest [Line Items]
Vesting percentage	25%
Class D Incentive Units | Share-Based Payment Arrangement, Tranche One
Noncontrolling Interest [Line Items]
Vesting percentage	25%
Class D Incentive Units | Share-Based Payment Arrangement, Tranche Three
Noncontrolling Interest [Line Items]
Vesting percentage	25%
Class D Incentive Units | Share-Based Payment Arrangement, Tranche Two
Noncontrolling Interest [Line Items]
Vesting percentage	25%
Redeemable non controlling interests
Noncontrolling Interest [Line Items]
Redeemable noncontrolling interest, equity, carrying amount	$ 3,709,231		$ 3,547,765	$ 2,901,899
Preferred share Accretion adjustment	$ 161,466		$ 645,866
Series B Preferred Stock | Levo Mobility LLC
Noncontrolling Interest [Line Items]
Temporary equity, shares authorized (in Shares) | shares	1,000,000
Temporary equity, dividend rate, percentage	8%
Temporary equity, par value (in Dollars per share) | $ / shares	$ 1,000
Temporary equity, accretion of dividends	$ 395,898
Temporary equity, shares issued (in Shares) | shares	3,138
Temporary equity, shares outstanding (in Shares) | shares	3,138

Non-Controlling Interest - Seri

Non-Controlling Interest - Series B Preferred Stock (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Noncontrolling Interest [Line Items]
Temporary equity, shares authorized (in Shares)	1,000,000	1,000,000
Temporary equity, shares outstanding (in Shares)	3,138	3,138
Temporary equity, shares issued (in Shares)	3,138	3,138
Temporary equity, par value (in Dollars per share)	$ 0	$ 0
Temporary equity, liquidation preference	$ 3,533,898	$ 3,464,606
Series B Preferred Stock | Levo Mobility LLC
Noncontrolling Interest [Line Items]
Temporary equity, shares authorized (in Shares)	1,000,000
Temporary equity, shares outstanding (in Shares)	3,138
Temporary equity, shares issued (in Shares)	3,138
Temporary equity, par value (in Dollars per share)	$ 1,000
Redeemable noncontrolling interest, equity, fair value	$ 3,138,000
Temporary equity, accretion of dividends	395,898
Temporary equity, liquidation preference	$ 3,533,898

Non-Controlling Interest - Non-

Non-Controlling Interest - Non-controlling interests presented as a separate component of stockholders’ equity (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance	$ (3,950,186)
Net income (loss) attributable to non-controlling interests	6,288	$ (100,933)
Less: dividends paid to non-controlling interests	69,292	64,015
Non-controlling interests	(4,174,656)		$ (3,950,186)
Levo Mobility LLC
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance	(3,950,186)	$ (2,501,633)	(2,501,633)
Net income (loss) attributable to non-controlling interests	6,288		(538,841)
Less: dividends paid to non-controlling interests	69,292		263,846
Less: Preferred share accretion adjustment	161,466		645,866
Non-controlling interests	$ (4,174,656)		$ (3,950,186)

Non-Controlling Interest - Cond

Non-Controlling Interest - Condensed consolidated statements of operations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Levo Mobility LLC
Noncontrolling Interest [Line Items]
Net income (loss) attributable to non-controlling interests	$ 6,288	$ (100,933)

Non-Controlling Interest - Rede

Non-Controlling Interest - Redeemable noncontrolling interest reconciliation (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Increase (Decrease) in Temporary Equity [Roll Forward]
Ending balance	$ 2,640,394
Redeemable non controlling interests
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	3,547,765	$ 2,901,899
Preferred share Accretion adjustment	161,466	645,866
Ending balance	$ 3,709,231	$ 3,547,765

Noncontrolling Interest - Sched

Noncontrolling Interest - Schedule of Monte Carlo Simulation model to estimate the fair value of class D incentive Units (Details) - Class D Incentive Units	3 Months Ended
	Mar. 31, 2023
Noncontrolling Interest [Line Items]
Expected life of options (in years)	5 years 6 months
Risk-free interest rate	3.02%
Volatility	69.50%

Noncontrolling Interest - Sch_2

Noncontrolling Interest - Schedule of nonvested Class D Incentive Units (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Weighted- Average Grant Date Fair Value($)
Reversal of previously recognized compensation expense for forfeited shares | $	$ 421,371
Class D Incentive Units
Shares
Beginning balance (in Shares) | shares	250,000
Granted (in Shares) | shares	0
Vested (in Shares) | shares	0
Cancelled (in Shares) | shares	200,000
Ending balance (in Shares) | shares	50,000
Weighted- Average Grant Date Fair Value($)
Beginning balance (in Dollars per share) | $ / shares	$ 13.28
Granted (in Dollars per share) | $ / shares	0
Vested (in Dollars per share) | $ / shares	0
Cancelled (in Dollars per share) | $ / shares	13.28
Ending balance (in Dollars per share) | $ / shares	$ 13.28

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)					1 Months Ended	3 Months Ended
	Apr. 14, 2023	Feb. 17, 2023	Jan. 31, 2023	Jul. 27, 2022	May 02, 2023	Mar. 31, 2023	Mar. 31, 2022	May 17, 2021
Subsequent Event [Line Items]
Proceeds from common stock offering, net of offering costs						$ 136,717	$ 0
Sale price (in Dollars per share)								$ 50
Registered Direct Offering
Subsequent Event [Line Items]
Per unit price (in Dollars per share)		$ 0.92
Proceeds from common stock offering, net of offering costs		$ 500,000
Agent fee percentage		6%
At The Market Offering
Subsequent Event [Line Items]
Sale of units (in Shares)						78,638
Proceeds from common stock offering, net of offering costs						$ 100,000
Agent fee percentage			3%
Sale price (in Dollars per share)						$ 1.79
Common Stock
Subsequent Event [Line Items]
Sale of units (in Shares)				2,150,000
Common Stock | Registered Direct Offering
Subsequent Event [Line Items]
Sale of units (in Shares)		543,478
Subsequent Event | Registered Direct Offering
Subsequent Event [Line Items]
Per unit price (in Dollars per share)	$ 0.55
Proceeds from common stock offering, net of offering costs	$ 1,000,000
Agent fee percentage	6%
Subsequent Event | At The Market Offering
Subsequent Event [Line Items]
Sale of units (in Shares)					179,326
Proceeds from common stock offering, net of offering costs					$ 98,023
Sale price (in Dollars per share)					$ 0.56
Subsequent Event | Common Stock | Registered Direct Offering
Subsequent Event [Line Items]
Sale of units (in Shares)	1,818,181